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CHAPTER 1: INTRODUCTION 
1.1 Hereditary cancer predisposition  
Cancer is a complex disease defined by uncontrolled cell growth that eventually leads to 
cells invading other nearby organs. It remains one of the leading causes of morbidity and 
mortality worldwide and places an enormous financial burden on those affected. Startlingly, the 
estimated financial annual cost of cancer is projected to reach $158 billion by 2020 in the US 
alone (Mariotto et al., 2011).  There are over 100 types of cancer, classified by the organ of 
origin.  What causes this uncontrolled growth is not always clear.  The advent of molecular 
profiling has helped to uncover mechanisms underlying tumor development and at the same time 
has helped to further classify tumors by sub-type.  Decades of research have shown various 
environmental carcinogens to play a role as well as genetic and epigenetic contributions.  
Tumorigenesis is a multistep genetic process and usually begins with a somatic mutation 
in a tumor suppressor gene (involved in DNA repair, apoptosis, etc.) or oncogene.  For tumor 
suppressor genes, an additional somatic mutation causing a loss of heterozygosity (LOH) of the 
wild type (WT) allele is often necessary for tumor progression. This observation confirmed 
Knudson’s two-hit hypothesis (Knudson, 1971).  Individuals who carry a germline variant in a 
tumor suppressor gene are at significantly higher risk than the general population as they are 
born already with the “first hit”.  These individuals are said to have an inherited cancer risk 
predisposition (Figure 1).  
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Figure 1.  Non-hereditary and hereditary initiation of tumorigenesis by two-hit hypotheses 
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1.2  Ovarian cancer  
Ovarian cancer (OVCA) begins in the ovaries or Fallopian tubes, which are part of the 
female reproductive system (Figure 2). Ovaries are almond in size and shape and are responsible 
for ova and female hormone production. Ovarian cancer is less common than other cancers, such 
as breast or colon cancer, and accounts for approximately 3% of all of cancers in women 
(National Cancer Institute, 2013).  Still, it is estimated that over 21,000 new cases of ovarian 
cancer occur yearly, in the United States alone (American Cancer Society, 2014).  Yet, despite 
being ranked as the 11
th
 most common cancer in women, it is the 5
th
 leading cause of cancer-
related death among women, and is the top cause of female reproductive cancer deaths (Bell et 
al., 2011).  The five year survival rate at diagnosis averages just 44.2% (American Cancer 
Society, 2014).  The high mortality rate is mostly due to poor early detection as only 15% of 
patients are diagnosed in early, more treatable stages (National Cancer Institute, 2013).  Accurate 
risk prediction holds promise as prophylactic measures can be taken before the cancer develops 
(Bast, Hennessy, and Mills, 2009). 
Recent studies suggest that at least 25% of epithelial ovarian cancer cases arise due to an 
inherited risk factor (Walsh et al., 2011).  Hereditary breast and ovarian cancer (HBOC) 
syndromes are, for the most part, autosomal dominant genetic disorders in which germline 
mutations elevate lifetime risk of developing breast or ovarian cancer up to as much as 87% and 
49% respectively (Antoniou et al. , 2003; Risch et al. , 2001; Claus et al. , 1996).  The risk 
among the general population is 12% for breast and 1.4% for ovarian cancer (Plevová et al. 
2009).  Therefore, women with a personal or family history of OVCA and/or young onset and/or 
multiple cases of breast cancer are counseled to consider genetic screening per guidelines of the 
National Comprehensive Cancer Network (NCCN) (Genetic/Familial High-Risk Assessment: 
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Breast and Ovarian www.nccn.org). Current testing panels mostly feature genes involved in 
DNA repair and cell cycle control, such as BRCA1 and BRCA2, which explain the majority of 
inherited ovarian and breast cancer, as well as 22 other genes including ATM, BARD1, BRCA1, 
BRCA2, BRIP1, CDH1, CHK2, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, 
RAD50, RAD51C, RAD51D, SMARCA4, and TP53.  Additional genes tested that are not directly 
involved with DNA repair or cell cycle control include; EPCAM, NF1, PTEN and STK11. 
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Figure 2. Diagram of the female reproductive system 
Source: https://www.womenshealth.gov/cancer/ovarian-cancer.  This image is free of copyright 
restrictions and may be copied, reproduced, or duplicated without permission of the Office on 
Women’s Health in the U.S. Department of Health and Human Services 
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1.2.1 Diagnostics and detection 
While significant advances in diagnosis and treatment for various other forms of cancer 
have led to excitement in the field of oncology, OVCA mortality rates have only slightly 
decreased since "the war on cancer" was officially declared in 1971 (NIH Surveillance, 
Epidemiology and End Results Program: Cancer of the Ovary - Cancer Stat Facts, 2017).  This is 
mostly due to a lack of advancement in early detection since survival rates depend greatly on the 
stage at which the cancer is diagnosed.  Women diagnosed before the cancer has had a chance to 
metastasize have a dramatically increased five-year survival rate relative to those diagnosed at a 
more advanced stage. The 5-year survival rate is over 90% with diagnosis at stage I and standard 
treatment. Unfortunately, less than 20% percent of OVCA patients are diagnosed in the early 
stages of the disease (National Cancer Institute, 2013).  Ovarian cancer is difficult to detect early 
since a woman may be asymptomatic until the cancer has advanced to Stages 3 and 4.  Unlike 
breast cancer, tumors that grow in the ovaries or Fallopian tubes are not readily detectable by 
self-examination.  When symptoms do appear, they are often vague and may not illicit 
immediate medical care. Symptoms include: abdominal pain, vaginal bleeding, weight loss, 
abnormal periods, back pain, bloating, nausea and vomiting, etc (NIH, 2017).  Therefore, 
accurate risk assessment to identify likely cases prior to occurrence holds much promise since 
prophylactic surgery can virtually eliminate a woman’s chances of developing OVCA. 
1.2.2 Risk factors   
Today, in the United States, the average woman’s lifetime risk of developing invasive 
ovarian cancer is 1 in 75 (National Cancer Institute 2013; Risk Factors - Ovarian Cancer 
Research Fund Alliance, 2017).  While women of all ages are susceptible to developing ovarian 
cancer, incidences are highest in women 55-64 years of age (National Cancer Institute, 2013; 
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Risk Factors - Ovarian Cancer Research Fund Alliance, 2017). There are, in addition to age, 
multiple factors that affect a women's lifetime risk. Caucasian ancestry, nulliparity, infertility, 
the use of hormonal replacement therapy, and obesity have all been found to correlate with an 
increased risk (National Cancer Institute, 2013; Risk Factors - Ovarian Cancer Research Fund 
Alliance, 2017).  The reproductive history is thought to be important to ovarian cancer risk since 
the risk increases with the amount of menstrual cycles a woman has during her fertile years.  
Therefore, a woman is at an increased risk if she has never had any children, has begun 
menstruation before the age of 12, started menopause after 50, or has never used oral 
contraceptives or undergone tubal ligation (National Cancer Institute, 2013; Risk Factors - 
Ovarian Cancer Research Fund Alliance, 2017).  
However, none of these factors are strong enough to predict the risk of ovarian cancer 
occurrence with enough conviction as to prompt prophylactic surgery. The single most 
influential factor on a woman's risk is her family history (National Cancer Institute, 2013; Risk 
Factors - Ovarian Cancer Research Fund Alliance, 2017; Chun and Ford, 2012; Trifonov, 
Todorova, and Uzunova, 2001).  While the average woman’s lifetime risk is just 1.4%, those 
with a first degree relative diagnosed with OVCA have a 5% lifetime risk (Centers for Disease 
Control and Prevention, 2017).  Therefore, women with a family history of ovarian cancer are 
encouraged to undergo genetic risk assessment. 
1.3 Genetic risk assessment 
Hereditary breast and ovarian cancer (HBOC) syndromes are for the most part autosomal 
dominant genetic disorders where germline mutations elevate lifetime risk of developing breast 
or ovarian cancer up to 87% and 49% respectively (Risch et al., 2001; Claus et al., 1996).  
Genetic testing can identify those at risk before the cancer develops, which in some cases leads 
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to prophylactic measures.  For those already with a diagnosis, testing for germline mutations can 
inform risk of additional cancers as well as identify risk in unaffected relatives who may also 
carry the same mutation. Therefore, identifying those at increased risk due to genetic inheritance 
can lead to improved clinical outcomes (Narod et al., 2013).  A diagnosis of HBOC is considered 
when either ovarian or breast cancer occurs on the same side of a family for multiple generations 
or multiple first-degree relatives (Kobayashi et al., 2013). Specifically, the likelihood of familial 
risk for HBOC increases with each of the following criteria (Clinical, Guidelines, and Guidelines 
2018): 
 A diagnosis of breast or OVCA under the age of 45  
 OVCA at any age 
 A blood relative diagnosed with breast cancer before 50 years of age 
 Breast/OVCA across multiple generations on the same side of the family  
 A second diagnosis of breast cancer or ovarian cancer in the same individual 
 Breast cancer in a male blood relative 
 Breast or ovarian and pancreatic cancer all on the same side of the family 
 A history of cancer in a family of Ashkenazi Jewish ancestry 
Two genes commonly associated with HBOC are BRCA1 and BRCA2, while other less 
common mutations have been found in tumor suppressor genes such as TP53, PTEN, CDH1, 
ATM, CHK2 or PALB2, etc. (Kobayashi et al., 2013).  Another inherited syndrome, Lynch 
Syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC) has also been 
linked to ovarian cancer with a 12% lifetime risk (National Comprehensive Cancer Network, 
2016).  Because of the heterogeneity of inherited OVCA risk, testing clinics currently offer large 
genetic sequencing panels which include all 24 genes known to associate with increased risk of 
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breast, ovarian, and/or uterine cancers; ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHK2, 
EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, 
RAD51C, RAD51D, SMARCA4, STK11, TP53.   
1.4 Genetic Penetrance 
The proportion of individuals carrying a variant (allele) of a gene that also express the 
trait associated with that variant is referred to as penetrance.  The degree of penetrance for 
disease associated genetic loci varies greatly. Some mutations have complete penetrance, 
meaning all individuals with the mutation have or will develop the disease (e.g Cystic Fibrosis, 
Huntington’s disease).  Most cancer-associated risk loci have incomplete penetrance, and many 
carriers of the risk mutation may never develop cancer.  BRCA1 is the most highly penetrant 
gene in hereditary breast and ovarian cancer syndrome with an 80% lifetime risk of breast cancer 
and up to a 50% lifetime risk of OVCA (Risch et al., 2001; Claus et al., 1996; Hereditary Breast 
and Ovarian Cancer | Cancer.Net, 2017).  Because clinical decisions such as prophylactic surgery 
and chemo-preventative therapies are made based on risk assessment, accurate penetrance 
estimates of cancer-associated loci is invaluable.  Currently, genes known to be mutated in 
hereditary cancer syndromes are referred to as having high, moderate, or low penetrance (Table 
1, Stanislaw C., 2016).  Unfortunately, penetrance is particularly difficult to determine for many 
cancer-associated risk loci as pathogenic variants in these highly conserved genes tend to be rare.  
In addition, environmental factors as well as other genetic and epigenetic alterations can 
contribute, meaning penetrance can vary based on the carrier. Therefore, germline mutations in 
cancer-associated genes are often described as having an unknown penetrance.   
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Table 1. Penetrance varies by gene and is often unknown. Table adapted from “Genetic 
evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing”  
Stanislaw C., 2016. 
 
 
 
PENETRANCE GENE CANCER RISK and GUIDELINES FOR 
CLINICAL MANAGEMENT  
High BRCA1 
BRCA2 
APC 
PTEN 
TP53 
MLH1 
MSH2 
MSH2 
PMS2 
STK11 
CDH1 
MUTHY 
Strong evidence for increased risk with 
well-defined risk profiles, prophylactic 
surgery or other preventative measures 
advised 
Moderate ATM 
CHEK2 
PALB2 
Moderate evidence for increased risk of 
certain cancers, increased surveillance 
advised  
Low/unknown  RAD50 
RAD51C 
RAD51D 
BRIP1 
BARD1 
POLE 
POLD1 
Varied evidence with clinical management 
based on personal and family history 
11 
 
 
 
1.5 BRCA1 and BRCA2 
Both BRCA1 (breast cancer type one susceptibility) and BRCA2 (breast cancer type two 
susceptibility) are tumor suppressor genes necessary for genomic stability.  Carriers of a 
pathogenic mutation in either gene are at a greatly increased risk of multiple types of cancer, 
most notably breast and ovarian.  These two genes account for 5 to 10% of all OVCA cases 
(Ramus and Gayther, 2009).  In the general population, approximately 1 in 400 people have a 
BRCA1/2 mutation that leads in increased cancer risk (PDQ Cancer Genetics Editorial Board 
2002).  The prevalence of BRCA1/2 pathogenic mutations is particularly high for certain 
ethnicities, specifically among Ashkenazi Jews where 1 in 40 are carriers of pathogenic founder 
mutations (Robles-Díaz et al., 2004). Both genes have been well characterized and are involved 
in numerous cellular processes important for genomic stability.  
BRCA1 encodes for an E3 ubiquitin-protein ligase that facilitates a diverse range of 
cellular processes including DNA damage repair, cell cycle control, apoptosis, transcriptional 
regulation and embryonic development (W. Wu et al., 2008).  BRCA1 interacts with numerous 
proteins by taking part of large complexes required for these pathways.  For instance, BRCA1 
has been shown to interact with RNA polymerase II for regulation of p21 in response to DNA 
damage (Moisan and Gaudreau, 2006), is involved in the MRE11-RAD50-NBS1 (MRN) 
complex (L. Chen et al., 2008), as well as binds BRCA2 and RAD51 for homology directed 
repair of double stranded DNA breaks (J. J. Chen et al., 1999).  BRCA1 has also been shown to 
regulate chromatin remodeling via the SWI/SNF complex (Bochar et al., 2000) and ubiquitinates 
RBBP8 for CHK1 mediated G2/M cell cycle control (Yarden et al., 2012).  
Similarly, BRCA2 is also involved in numerous cellular processes required for genomic 
stability. These biological processes include DNA repair, cell division, histone acetylation, and 
12 
 
 
 
replication fork maintenance. BRCA2 selectively binds to ssDNA and mediates HRR by aiding 
in RAD51 ssDNA assembly and stabilization. This enables RAD51 to displace replication 
protein-A (RPA) which binds single strand DNA (ssDNA) during the initial steps of DNA repair 
(J. J. Chen et al., 1999). BRCA2 forms a complex with PALB2 to direct the localization of 
POLH to collapsed replication forks (Buisson et al. 2014).  In addition, this interaction is part of 
a complex including RAD51C and involved in DNA repair by HRR (Sy et al., 2009).  BRCA2 
also regulates centrosome duplication via NPM1 (H. F. Wang et al., 2011).  The BRCA2 protein 
likely has additional functions yet to be verified. For example, it is suspected to play a role in S 
phase checkpoint activation (Yoshida and Miki, 2004) and prevent R-loop DNA damage 
incurred through the transcription process (Bhatia et al., 2014).  
1.6 Missing heritability 
For complex traits such as susceptibility to cancer it is possible to establish an estimate of 
how much of the phenotypic variance is due to genetic inheritance. One classic means of 
determining the heritability of a trait is through twin studies that measure the similarity of a trait 
between monozygotic twins as compared to dizygotic twins.  Monozygotic twins are derived 
from a single fertilized egg and thus share the same genetic material while dizygotic twins, 
formed from separate eggs, share about half of their genes.  Because both sets of twins share the 
same environment, at least in childhood, this approach controls for much of the environmental 
contribution to cancer risk.  If monozygotic twins resemble each other more than dizygotic twins 
for a particular trait, then the heritability of that trait is estimated as twice the observed 
difference.   
Using this approach, a high amount of heritability has been observed in various types of 
cancers, including melanoma (58%), prostate (57%), ovary (39%), and breast (31%) amongst 
13 
 
 
 
others (Mucci et al., 2016). However, as with many multifactorial diseases, there is a gap in our 
knowledge of the genetics underlying the predisposition.  Often, the known genetic variation 
attributed to a disease do not account for its total estimated heritability.  This is referred to as ‘the 
missing heritability issue’. For certain diseases, this unexplained heritability often limits how 
informative genetic testing can be.  Specifically, while ovarian cancer is demonstrated to have a 
strong genetic component, the known risk loci cannot account for the majority of the familial 
risk.  Therefore, many women with compelling personal and or family histories regularly test 
negative for the currently described susceptibility loci (Stafford et al., 2017). 
1.7 Variants of unknown significance  
Rare and private mutations are likely to account for much of the missing heritability in 
ovarian cancer. This hypothesis is supported by the fact that many women who undergo genetic 
testing are found to have a “variant of unknown significance” (VUS) (Stafford et al., 2017; 
Towler et al., 2013; Domchek and Weber, 2008).  The term “VUS” is used to describe a rarely 
seen mutation, unannotated in its functional consequence on the protein or disease risk. 
Assessing these variants is crucial for accurate risk assessment, prevention and targeted therapy.  
Yet we currently lack a means to functionally validate private mutations in a clinical setting 
(Towler et al., 2013). The American College of Medical Genetics and Genomics (ACMG) 
provides detailed guidance as to the interpretation of genomic variants (Richards et al., 2015) 
(Table 2).  However, in the case of a missense change, it is difficult to obtain strong evidence for 
pathogenicity, especially when rare. Therefore, the vast majority of compelling sequence 
changes remains annotated as having only moderate evidence as to its pathogenicity.   
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ACMG Evidence for Pathogenicity: 
VERY STRONG • Loss of function variant in a cancer-associated gene 
STRONG • Functional assay supportive of damaging effect 
• Increased prevalence in cases versus controls (O.R. >5) 
• Co-segregation with disease in multiple affected family members 
MODERATE • In a mutational hot spot or well-established functional domain 
• Extremely low frequency or absent from ExAC, 1000 genomes  
• In-frame deletions/insertions   
• Co-segregation with disease in multiple affected family members 
• Multiple lines of computational evidence 
 
Table 2. ACMG Evidence for Pathogenicity. Simplified and adapted from “Standards and 
guidelines for the interpretation of sequence variants: a joint consensus recommendation of the 
American College of Medical Genetics and Genomics and the Association for Molecular 
Pathology”  
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1.8 Implicating novel risk loci 
When a trait or disease is suspected to be inherited, there are various approaches that can 
be employed to identify the genes and variants responsible.  One approach is through linkage 
analysis, a hypothesis-neutral means to find segments of DNA which all affected persons of a 
family share but the healthy relatives do not have.  This is possible because genetic variants that 
are close in proximity tend to be inherited together. The analysis begins with genotyping genetic 
“markers” (highly variable regions of the DNA) on each chromosome for both affected and 
unaffected individuals of a family.  Once a region is identified as shared between and unique to 
those affected, additional markers are added to further narrow the search within this region until 
a specific gene and genetic variant is implicated.  This method is most appropriate when 
attempting to map monogenic disease mutations and requires large families.   
For complex traits and disease predisposition, a better approach to implicating genetic 
variants is through association, such as a Genome Wide Association Study (GWAS). These 
studies look for genomic variants that are statistically more prevalent in cases versus controls by 
genotyping across the entire genomes of hundreds or thousands of individuals both with and 
without the trait/disease of interest.  GWA studies rely heavily on the “common disease, common 
variant” (CDCV) assumption and are typically designed to exclude SNPs with a MAF < 5% 
(Visscher et al., 2012).  They lack the statistical power necessary to detect rare variants, which 
are more likely to have a high effect.  Therefore, GWA studies are best for implicating common 
and low risk alleles that are not clinically actionable.  
High-throughput sequencing using next generation technology allows for a more efficient 
and unbiased approach in the discovery of novel cancer predisposition loci and has helped to 
determine the frequency of germline mutations in HBOC.  However, because of the rarity of 
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ovarian cancer, large cohorts are obtained by recruiting participants that are not selected based 
on family history.  This means that, in large studies, most of the underlying etiology is sporadic, 
and the majority of the causal variants uncovered are in BRCA1 and BRCA2, genes with already 
well-established roles in OVCA.  For example, a recent publication reports the results of 
sequencing 1915 patients with OVCA and found that of these cases, 347 (18%) carried 
pathogenic germline mutations in genes associated with OC risk, 80% of which were in BRCA1 
and BRCA2 (Norquist et al., 2015).   Because patients were not selected for age or family history, 
the vast majority of cases in this cohort are sporadic and not due to an underlying inherited risk.  
This type of study, while impressive in size, is limited to estimating the prevalence of known 
pathogenic mutations in the study population.   
Hereditary OVCA is a rare disease with a high degree of genetic heterogeneity.  
Therefore, despite the fact that any women with a diagnosis of OVCA is considered at risk of 
possible germline risk, the best study design for identifying novel putative risk loci includes a 
much stricter selection of patients.  The most appropriate study sample would include only 
OVCA patients with a suspicious family history indicating genetic inheritance of risk and would 
exclude those with known pathogenic variants (Stafford et al., 2017).  Candidate risk loci 
identified by the whole exome/genome sequencing of this sample would then be assessed by 
both bioinformatics and functional analysis.    
1.9 Gene panel vs whole exome sequencing for diagnostic purposes 
Because of the immense heterogeneity of inherited cancer risk, current testing is 
performed by analyzing a panel of associated risk genes to increase the chance of finding a 
causal genetic variant. However, despite the introduction of larger and more inclusive gene 
panels, issues of low diagnostic yield remain, and inconclusive results have brought an additional 
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burden of stress on clinicians, patients, and relatives.  Our knowledge regarding inherited cancer 
risk is still very incomplete.  Therefore, testing panels are frequently being updated and 
subsequently outdated and many who question the utility of panels favor a more practical whole 
genome/exome approach by which genes can be analyzed post hoc without the need for 
additional testing.  The future of genetic testing seems poised for this approach, but hesitation 
remains for various reasons.   
One valid argument against employing exome sequencing in place of panel testing is that 
it would sacrifice quality for quantity.  High quality variant calls are necessary for accurate 
clinical genetic diagnosis and whole exome sequencing (WES) is not ideal for detection of 
variants in regions high in GC content, with many repeats, or with homology to other areas of the 
genome (Sekhar et al., 2014).  In contrast, panel testing focuses on a small number of genes 
allowing for the luxury of more coverage, greater read depth, and thus higher quality variant 
calls.  Therefore, panels are traditionally believed to have superior detection of pathogenic 
variants and thus a better diagnostic yield.  However, as our technology advances and 
bioinformatic pipelines for variant calling improves, the quality of WES data will inevitably 
reach comparable clinical sensitivity if it has not yet already.  A recent study assessing the 
coverage in 100 samples demonstrated that 99.7% of pathogenic variants were detectable by 
WES at clinical sensitivity, and all had at least some coverage on exome sequencing (Laduca et 
al., 2017). Another study compared the diagnostic performance of WES to two panels, TruSight 
Cancer (94 genes) and another custom panel of 122 genes and identified a similar number of 
variant calls (amongst shared genes) despite greater average read depth in panels (Feliubadaló et 
al., 2017).  
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 Another important consideration besides call quality is cost.  However, the cost 
discrepancy between WES and panels is narrowing and the long-term benefits of exome 
sequencing may, in some cases, outweigh the difference.  While sequencing exomes is more 
expensive than sequencing panels, they provide additional patient data regarding genes that may 
one day be clinically relevant and is accessible without the need for retesting.  Panels can quickly 
become outdated with each novel gene discovery and insurance will often only cover genetic 
testing once.   
Yet another valid concern for molecular diagnostic labs is testing turn-around time.  
Many smaller labs may not be set up for WES on so many samples and sometimes immediate 
clinical decisions are based on mutational status. Therefore, when to choose exome sequencing 
over panel testing should be made on a case by case basis.  Currently, as a first step into this new 
era, WES may only be necessary in cases suspected to have inherited risk.  For instance, NCCN 
guidelines stipulate that women diagnosed with ovarian cancer are eligible for genetic testing 
regardless of family history (“National Comprehensive Cancer Network. Panel Members 
Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 1), 2018). While panel 
testing is likely sufficient for most cases, those patients with a family history of breast or ovarian 
cancer may benefit more from whole exome sequencing.  
1.10 DNA repair and genomic integrity 
The integrity of an organism’s genetic material is essential to its survival.  However, our 
DNA is constantly being damaged during the process of cellular metabolism as well as by 
external environmental assaults such as radiation.  Consequently, all forms of life have 
developed the ability to identify and repair these genomic lesions. While there exist many types 
of DNA lesions, the most harmful is the double strand break (DSB).  DSBs occur due to 
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exposure to ionizing radiation (IR), various chemotherapeutic reagents, reactive oxygen species 
(ROS) generated by cellular metabolic processes and in certain circumstances during DNA 
replication (Mehta and Haber, 2014).  DSBs that go unrepaired can lead to a deletion, 
amplification or even translocation of genetic material, potentially at a locus encoding for a 
tumor suppressor or oncogene.   Therefore, effective repair of DSBs by either homologous 
recombination repair (HRR) or non-homologous end joining (NHEJ) is crucial to avoid 
tumorigenesis.  
1.10.1 Homologous recombination repair  
Homologous recombination repair (HRR) is a highly conserved and non-error prone 
process that corrects DSBs using the sister chromatid as a template for gene conversion (Figure 
3). Therefore, this mechanism can only be employed during G2 and S phase of the cell cycle, 
when a homologue is available.  Shortly after the double strand lesion occurs, HRR is initiated 
by the phosphorylation of H2AX at Ser139 by ATM or ATR (Helt et al., 2005; Rogakou et al., 
1998).  Phospho-H2AX (γH2AX) recruits various proteins to the damaged DNA, most notably 
MRE11, RAD50 and NBS1 which form the MRN complex.  This complex binds the broken ends 
of the DNA for stability, likely preventing additional breakage in addition to initiating DNA 
strand resection by endonuclease MRE11 (Lamarche, Orazio, and Weitzman., 2010).  The 
resection creates single-stranded DNA (ssDNA) which is stabilized by Replication Protein A 
(RPA) and acts as a probe in the search for a homologous sequence.  Next, the broken strand 
invades the sister chromatid through the action of RAD51, which replaces the RPA through the 
action of BRCA2 (Buisson et al.. 2010).  RAD51 then replaces RPA and forms filaments on the 
DNA necessary for the strand exchange between homologous sequences (Buisson et al. 2010).  
Synthesis of the missing DNA segment is filled in by replication machinery PCNA and 
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polymerase δ and ε (Sneeden et al., 2013).  Finally, the connected segments of the two DNA 
molecules (Holliday junction) are resolved by nucleases.  
1.10.2 Non-homologous end joining 
Another pathway for DSB repair is Non-Homologous End Joining (NHEJ).  During this 
process, breaks in DNA are corrected by a direct ligation of the blunt ends and thus do not 
require a homologue to serve as a template. While this mechanism is more error prone, it is the 
most reliable mechanism for DSB repair in post-mitotic cells. NHEJ involves three basic steps: 
DNA DSB damage recognition, processing of break ends, and strand ligation (Figure 3). In 
NHEJ, DSBs are quickly recognized by heterodimer KU70/KU86 (KU80) which act to both 
protect the strand ends from degradation as well as recruit DNA-PKcs, the catalytic subunit of 
DNA dependent protein kinase (Jin and Weaver, 1997). End processing may occur before 
ligation and may involve several enzymes including a nuclease (ARTEMIS), polymerases, 
polynucleotide kinase/phosphatase (PNKP), and Aprataxin (APTX) among others (Povirk, 
2012). For ligation of the processed break ends, both DNA ligase IV and XRCC4 are recruited 
and activated via phosphorylation by DNA-PKcs (Povirk, 2012).  
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Figure 3. Schematic illustration of the repair of a DNA DSB by homologous recombination 
repair (HRR) and non-homologous end joining (NHEJ). Image Source: 
https://www.intechopen.com/books/new-research-directions-in-dna-repair/radiosensitization-
strategies-through-modification-of-dna-double-strand-break-repair. Permission of image use 
granted by Dr. Yoshihisa Matsumoto, Tokyo Institute of Technology. 
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1.11 Targeted therapy in clinical cancer care 
Our greater understanding of the molecular genetics underlying tumorigenesis has led to 
a whole new field of precision medicine in which therapies are developed to target specific 
“drivers” or deficiencies that encourage cancer progression.  What initiates or “drives” the 
process of tumorigenesis and metastasis differs by cancer subtype and even by individual tumor. 
Tumor sequencing has thus become a routine practice in clinical cancer care to inform 
therapeutic decisions.  For instance, the most common driver of tumorigenesis in breast and 
ovarian cancer is genomic instability due to inefficient DNA repair by homologous 
recombination (Spring and Perspect 2015; van Gent and Kanaar 2016).  Platinum-based agents, 
the first-line therapy for these tumors, exploit this deficiency by causing DSBs vis intra and 
interstrand DNA crosslinking (Ph and Andrea, 2016).  Cancer cells are most sensitive to this 
drug as they lack the ability to repair these breaks and damage will accumulate leading to 
eventual cell death.  
Another targeted therapy often used in conjunction with platinum in breast and ovarian 
cancer is polyADP-ribose polymerase (PARP) inhibitors (PARPi). The PARP family of proteins 
is involved in a form of ssDNA repair known as Base Excision Repair (BER). Cancer cells 
deficient in other DNA repair mechanisms are more dependent on the PARP proteins.  By 
inhibiting this pathway, the cell loses its ability to repair DNA leading to synthetic lethality.  
Tumor cells with mutant BRCA1 and/or BRCA2 have demonstrated to be up to 1000 times more 
sensitive to PARPi as compared to WT cells (Farmer et al., 2005; Bryant et al., 2005).  In clinical 
trials, the use of PARPi has shown to improve progression-free survival when added to the 
treatment of women with breast or ovarian cancer responsive to platinum (Robson et al. 2017; 
Ledermann, 2016; Evans and Matulonis, 2017).
 
 More recently, investigators have identified an 
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additional mechanism of action for PARPi.  PARP proteins were found to localize at DNA 
damage sites and become trapped on the DNA when bound to an inhibitor, blocking DNA 
replication, and causing cell toxicity (Lord and Ashworth, 2017).  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Sample ascertainment and description 
Study samples were acquired through the Karmanos Cancer Institute Genetic Registry 
(KCIGR), an IRB approved biospecimen repository comprising females with a personal or 
family history of breast and/or ovarian cancer and at elevated risk of harboring a BRCA1/2 
mutation.  Over 800 DNA samples from breast and/or ovarian cancer patients were collected 
spanning the years of 1999-2013, when HBOC genetic screening was limited to BRCA1/2 and 
risk assessment was performed using BRACAPRO and Myriad II, which were the standard of 
care during the duration of accrual.  BRCAPRO is a computer-based Bayesian probability model 
that uses breast and/or ovarian cancer family history to determine the probability that a BRCA1 
or BRCA2 mutation accounts for the pattern of these cancers in the family (Parmigiani, Berry, 
and Aguilar, 1998).  Key attributes of consideration include the population prevalence of BRCA 
mutations, age-specific penetrance, and Ashkenazi Jewish heritage.  Myriad II is a set of 
prevalence tables categorized by ethnic ancestry (Ashkenazi Jewish or non-Ashkenazi Jewish), 
breast cancer age of onset (age ≤50 years), and the presence of ovarian cancer, in the patient 
and/or first- or second-degree relatives.  Myriad II is based on historical test data from the 
Myriad Genetic Laboratories clinical testing service (Frank, 1999).   
Through the KCIGR biospecimen repository, we obtained 89 DNA samples from high 
risk Caucasian women with a personal history of OVCA.  Participants were either confirmed 
BRCA1/2 mutation carriers or BRCA1/2 negative after full gene sequencing, BART 
(BRCAnalysis rearrangement test) or testing for the three common Ashkenazi Jewish mutations 
(Myriad Genetics Laboratories, Salt Lake City, Utah).  Participants testing positive for 
pathogenic BRCA1/2 germline mutations were excluded from the study sample.  The final 
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sample consisted of 48 BRCA1/2 mutation negative Caucasian OVCA patients from 47 families 
(one mother-daughter pair).  All subjects provided written informed consent for the collection of 
blood samples and access to medical records.  The protocol (HIC#024199MP2F(5R)) was 
approved following Full Board Review by the Human Investigation Committee at Wayne State 
University, Detroit, Michigan.   
Information regarding tumor histology, tumor grade, age of diagnosis, and family history 
of study sample is summarized in Table 3.  Tumor histology from study sample patients included 
serous (n=26), endometrioid carcinoma (n=5), mixed (n=4) adenocarcinoma (n=2), mucinous 
(n=1), clear cell (n=1), and undefined (n=9).  Tumor grade included grade 2 (moderately 
differentiated, n=6), grade 3 (poorly differentiated, n=24), and grade 1 (well differentiated, n=1).  
Ovarian cancer was the primary diagnosis for 43 patients, while four had a primary diagnosis of 
breast cancer and one of cervical cancer followed by a secondary OVCA diagnosis.  Of those 
with a primary OVCA diagnosis, six had a secondary cancer diagnosis: two breast, two colon, 
one uterine and one melanoma.   
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Table 3. Tumor histology, tumor grade, age of diagnosis and family history of study 
sample 
 
 
 
Mean Age at Diagnosis 52.8 (yrs.) 25-81 (range) 
Histology n= % 
    Serous 26 54 
    Endometrioid 5 10 
    Mixed 4 8 
    Adenocarcinoma, NOS 2 4 
    Clear Cell 1 2 
    Mucinous 1 2 
    Unknown 9 19 
  Stage n= % 
    I 8 17 
    II 5 10 
    III 23 48 
    IV 3 6 
    Unknown 9 19 
Grade n= % 
    Grade 1- well differentiated 1 2 
    Grade 2- moderate 6 13 
    Grade 3- poor 24 50 
    Unknown 17 35 
Personal and Family History n= % 
personal BC/OVCA diagnosis < 50 yrs. of age 15 31 
personal second primary cancer diagnosis  12 25 
personal/family history of BC 31 65 
family history of OVCA 14 29 
family history of epithelial cancer 47 98 
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2.2 Whole exome sequencing  
DNA from peripheral blood samples was isolated by the Karmanos Applied Genomics 
Technology Center, Detroit, MI using QIAamp DNA mini kit (Qiagen) and whole exome 
sequencing (WES) was performed using Nextera Rapid Capture Kit. Samples were 
demultiplexed using Illumina’s CASAVA 1.8.2 software (Kumar et al., 2014). Read quality was 
assessed with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/2) and 
alignment to the human reference genome (hg19) (Lander et al., 2001) was performed using 
Burrows Wheeler Aligner (BWA) (Li and Durbin, 2009).  PCR duplicates were removed using 
Samtools, (Li et al., 2009) and subsequent local realignment, Qscore recalibration, variant calling 
and filtering was performed using Genome Analysis Toolkit (GATK) (DePristo et al., 2011) 
Unified Genotyper and Haplotype Caller.  SNPs were filtered out if: 1). Four or more alignments 
have mapping quality = 0 and the number of alignments that mapped ambiguously were more 
than 1/10 of all alignments for the given SNP.  2). SNP is represented by less than 5 reads 3). 
SNP quality is below 50 4. QD score (variant confidence) is below 1.5.  Variant files were 
constructed using Genome Trax BIOBASE biological databases analysis software 
(http://www.biobase-international.com) and annotated with Illumina BaseSpace VariantStudio 
application v2.2.4 (www.illumina.com) and snpEff (Cingolani et al., 2012).   
2.3 Panel and candidate genes analyzed 
Genes analyzed for potential risk variants included those currently featured on HBOC 
genetic testing panels by Ambry OvaNext and Myriad MyRisk: BRCA1, BRCA2, MLH1, MSH2, 
MSH6, PMS2, EPCAM, APC, MUTYH, CDKN2A, CDK4, TP53, PTEN, STK11, CDH1, 
BMPR1A, SMAD4, PALB2, CHK2, ATM, NBN, BARD1, BRIP1, RAD51C, RAD51D, in addition 
to 155 non-panel candidate genes important to DNA damage response or cell cycle regulation 
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and 64 genes listed as having disease causing mutations associated with OVCA in HGMD.  A 
full list of non- panel candidate genes analyzed is provided in Table 4. 
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Table 4.  Non-Panel genes analyzed for high impact variants Genes were chosen based on 
their involvement in either DNA repair cell cycle control, or due to being listed as having 
“disease causing mutations” (DM) associated with OVCA in HGMD. 
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2.4 In silico SNP assessment  
In silico variant assessment of single nucleotide polymorphisms (SNPs) was performed 
using online available bioinformatics tools, HGMD (Stenson et al., 2003), dbSNP (Sherry et al., 
2001), ExAC (http://exac.broadinstitute.org), SIFT (Ng, 2003) and PolyPhen (Gnad et al., 
2013).  Variants were stringently filtered to include only exonic SNPs most likely to have a 
moderate to high effect impact on protein function (frameshift, nonsense, and missense) while 
also rare, (<0.02 MAF ExAC; European, non-Finnish) and predicted to be damaging by SIFT 
and/or PolyPhen, which take into consideration parameters such as amino acid substitution and 
evolutionary conservation. Variants passing these criteria were confirmed by forward and reverse 
strand Sanger sequence (GENEWIZ, South Plainfield, NJ) unless otherwise specified.  
Additional bioinformatic resources were consulted to further describe variants including: dbSNP, 
UCSC Genome browser, and the Human gene mutation data base (HGMD) which lists variant 
risk predictions from Mutation predictor risk assessment, Likely hood ratio test for functional 
prediction (LRT), Mutation taster prediction, and Genomic Evolutionary Rate Profiling (GERP).  
2.5 Next generation sequencing validation 
Next generation sequencing and other high throughput methodologies are fast and 
efficient at the cost of accuracy.  Therefore, all variants of interest called by WES were validated 
by Sanger sequencing. Using the primers listed in Table 5, 400-700 bp DNA products, which 
included the variant of interest were amplified by PCR (Polymerase Chain Reaction) followed by 
agarose gel electrophoresis to check for amplification and possible contamination. The amplified 
DNA fragments were then purified by spin column and quantified before being sent out to 
GENEWIZ for Sanger sequencing.  
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2.5.1 Primer design  
Primers for PCR amplification and targeted sequencing were designed using Primer3Plus 
(http://www.bioinformatics.nl/cgi- bin/primer3plus/primer3plus.cgi), which includes information 
regarding primer binding specificity, GC percentage, and melting temperature (Table 5). 
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Table 5. Primers for the amplification and sequencing of indicated genomic loci 
Gene dbSNP ID   Variant Forward Sequencing Primer Reverse Sequencing Primer 
ATM N/A c.2503_2507del AAGAAGAACTTTCATTCTCAGAAGTAG TTTTTCATCATATAATCCCTATGCTC 
ATM N/A c.5697_5698insA TGGTGTACTTGATAGGCATTTGA TCTGAGCTTTTCCACACTGC 
ATM rs1800054 c.146C>G GAGCTACAGAACGAAAGGTAGTAAA TTTCCTCTAATCTGAAGTCTTGTGAA 
ATM rs138327406 c.4388T>G ATCAGAAAATTCTTCTTGCCATA CAGGAGGTTGAGGATGCAGT 
ATM rs28904919 c.998C>T TTTTGTGGGAGCTAGCAGTG GGTGGCTCATGCCTGTAATC 
ATM rs56009889 c.6919C>T GTGGGGAGATGTCATGCAG GGGACACCAATGCCTCTACTT 
ATM rs35203200 c.7618G>A CCTCAGATAAGAAAAGA TGCAGTGGGTAGAGCGTG 
AXIN1 rs143974067 c.1018G>A TTCCTGAAGACAAAGCCCAG  GTCACTAACATGCCCTGCTT 
BRCA1 rs4986852 c.3119G>A TCCCATAGGCTGTTCTAAGTTATCTG  CAGAGGCAACGAAACTGGACTCA 
BRCA1 rs1800744 c.4535G>T TTGAGCTATTTTTCTAAAGTGGGCTTA  AGGCAACATGAATCCAGACTTCTAG 
BRCA2 rs80358479 c.1889C>T GCCTCTGAAAGTGGACTGGA  GCAGGCATGACAGAGAATCA 
BRCA2 rs28897747 c.8149G>T TAAAACTAGTAGTGCAGATACCCAAAAAGTG  CAATGACTGATTTTTACCAAGAGTGCAAA 
BRCA2 rs11571747 c.8567A>C TGGAGGAAATGTTGGTTGTGTTGA  CCTTCATGTTCTTCAAATTCCTCCTGA 
BRCA2 rs11571833 c.9976A>T CACCTGTCTCAGCCCAGATGAC AGTTGTAATTGTGTCCTGCTT 
BUB1B rs28989188 c.1227A>C TTCCCCACTTTACGCTTTTG  ACCATAGAAGGCAGCAGTGG 
CHK1 N/A c.1564-1565insA TGAAGTGCCTCTAAAGTTTCCA  TGTTCACACAATGATGAAACCA 
CHK2 rs587780185 c.565A>G ATCACAGTGGCAATGGAACC CTCCCAAAGTGCTGGGATTA 
ERCC6 rs201486862 c.2137A>G TCGGATCATTCTGTCTGGCT ATGAGCCTGGCCATCTTTCT 
FANCM rs144567652 c.5713C>T TCTAGCACTTCAGGGGCATC TGAAGTGAGCTGTTAGCCATCC 
HMMR rs146791423 c.1054G>T ACCTCACAATGCCATTCCA AAGCTGAAAGGCTGGTCAAG 
MCM4 N/A c.1610-1611del  GCGGGACAAGGAAGGATTTT  CATGTTCACGGTGGAGAAGG 
MSH6 rs63751005 c.620T>C TGAACTGGGGCTGGTATTCA AAGCACACACCATATGCACG 
MUTYH rs34612342 c.494A>G GTCTCTTTCTGCCTGCCTGT CTACGTTGCCATCCACCAC 
MUTYH rs36053993 c.1145G>A AACACTGGACAGTGCCACCT AAGGGTCAAGGGGTTCAAAT 
NBN rs61754966   c.511A>G CAACAAAGAAATTTGGGGAAC GCAGTGACCAAAGACCGACT 
PALB2 rs45551636 c.2993G>A TTTGGCTTAGGGCATTGTTT GACATGTCTGGCTTCCACCT 
PALB2 rs45532440 c.2014G>C CCTGATGAAGACTTTGGACCTC TAAGATGGGGAAAGCAGGTG 
PALB2 rs200283306 c.3508C>T TCTGTCTGGACATAAACAAGCAA ACTCTCAGCGTGGGTGTGAT 
PALB2 rs45478192 c.2816T>G  ATCTTTCAGATTCTTTCAAGACTCAAGCC  CTGGATTAAACAAAAATGAAACAACCAAGC 
PALB2 rs45494092 c.1010T>C ATTTCACCAGGGCGACTACA TTGACTCAAAGGGCTCCACT 
PALLD rs138897963 c.909A>T ACCTCAGCAGATGTTGTGTC  ATGGGTGCCTAAATGTCGGA 
PMS2 rs200513014 c.1004A>G CAGTGGCTGCTGACTGACAT GTTGCAGTGAGCTGAGATCG 
POLK N/A c.1336del TGAATAGGCTATGGGAGAAAGAA GGCATTTATTGCAGGGAGTG 
POLQ rs148626322 c.7537C>T TCCCAAAGAGGGTTACAGGA AGGCTGAGCGTCAAGCTATC 
RAD1 N/A c.1154del CGGCCACCTTTAGACTCTTG TTGGGAGTTCTGAGCAGTGTT 
RAD51D rs587781756 c.511C>T CCTGCAGCAAAACGTCCTAT AGTAGGACACCTGCCCACAG 
RAD51D rs387906843 c.616C>T ACCACTGTGACAACTGACCA AGTAGGACACCTGCCCACAG 
RAD52 rs4987208 c.1245T>G TAGCAGGAAGCGGAAACG ACTGCAGTGGGCTCTCAGTC 
RAD52 rs4987207 c.806C>A TCCAGTTCCTCTTTGGTCCT AGGATCTCCCCTTAATTTTTGTG 
REC8 N/A c.1622G>A GACCTTCCCCCACTACACAG TGGGGATGGGAGAAGTAGAA 
RECQL rs150889040 c.962G>A  GAAGCTCTGACCATCCCTGA  CAACAGTTGCCACTACTACCTG 
TP53I3 rs145078765 c.755C>G TCTGAAATCGGGTTCCCTCT AGGCCTCATAAATGGTGAACTT 
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2.5.2 PCR amplification  
Polymerase chain reaction (PCR) is a frequently used method for the exponential 
amplification of short sequences of DNA.  PCR requires the use of primers (Table 5) that a 
thermo-stable DNA polymerase extends to replicate the target (HotStarTaq Plus DNA 
Polymerase, QIAGEN Fast Cycling PCR KitCat No./ID: 203743). Each round of amplification 
requires a three-stage temperature fluctuation process to facilitate the reaction (see PCR Protocol 
below).  For ample product yield, the thermocycler (Mastercycler, Eppendorf, Hamburg, 
Germany) was set for 36 rounds of amplification. 
PCR reaction set up            20 μl   
Qiagen Master Mix =         10 μl 
Primer (forward) =               2 μl 
Primer (reverse) =               2 μl 
DNA (25ng/μl) =                 2 μl            
sterile dH
2
0                      4 μl 
PCR protocol:  
1. Original denaturation: The DNA was heated at 95°C for 5 minutes to denature.  
PCR Cycle begins:  
2. Denaturation: 96°C for 5 seconds 
3. Primer Annealing: 55-62 °C (optimized for specific primer pair efficiency)  
4. Elongation: 68 °C for 15 seconds  
PCR Cycle ends (new cycle begins)  
5. Final elongation: After the last PCR cycle (36 in total), the reaction was incubated at 72 °C for 
2 minutes to ensure full extension of any remaining ssDNA.  
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2.5.3 Agarose gel electrophoresis 
Agarose gel electrophoresis is a simple method that separates DNA fragments by 
molecular weight/size.  DNA molecules carry a negative charge due to the phosphate backbone 
and migrate towards the positively charged end of an electric field.  For visualization, ethidium 
bromide is incorporated into the gel as it intercalates between the bases of dsDNA and fluoresces 
under UV light.  The size of the DNA fragment determines the speed at which it migrates.  The 
larger the fragment, the slower it will migrate through the porous gel. Therefore, DNA product 
size can be measured by comparison with a standardized ladder.  This method is used for the 
confirmation of PCR product and to identify possible contamination that occurred during the 
amplification process.  
Agarose Gel Electrophoresis Protocol: 1 g of agarose powder (Thermo Scientific, 
Waltham, MA, Cat# R0491) was dissolved into 100 ml of TAE buffer by boiling. 15μl of 
ethidium bromide was then mixed into the solution before allowing it to solidify in a gel forming 
tray.  Once solidified, the gel was placed onto an electrophoresis plate, and submerged in TAE 
buffer.  2μl of loading dye (QIAGEN Fast Cycling PCR KitCat ID: 203743) was added to the 
PCR product. 2μl of PCR product was loaded in each well.  For PCR product size measurement, 
2μl of a 100bp DNA ladder was also added. The gel was then given 45 minutes of a 400-mA 
current at 80 volts, followed by visualization using a UV source (Fisher Biotech, Wembley, 
Austrailia, Electrophoresis Systems). 
2.5.4 Sanger sequencing  
Sanger sequencing is a commonly employed method for the accurate sequencing of DNA 
using chain-terminating (dideoxy) nucleotides incorporated by a DNA polymerase during in-
vitro PCR amplification. Each nucleotide version, ddATP, ddTTP, ddCTP, ddGTP, is labeled 
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with a unique fluorescent dye so that during replication, DNA fragments are randomly 
terminated with the fluorescent label.  The amplified products are then separated by Capillary 
Array Electrophoresis (CAE), which detects fluorescently labeled fragments and provides an 
ordered sequence of the fragments based on product length to be computationally assembled. 
The Sanger method, developed in 1977 by Frederick Sanger, was once the most widely 
employed sequencing technology. While high throughput sequencing (Next Generation 
Sequencing) has become the current preferred methodology, Next-Gen results are often validated 
using Sanger sequencing as it is considered more reliable.  
Sanger Sequencing Preparation Protocol: PCR products were purified by spin column 
(Qiagen QIAquick PCR Purification Kit Cat# 28104) and quantified by spectrophotometer 
(NanoDrop 2000, Thermo Scientific).  PCR reactions were prepared before shipment to 
GENEWIZ and trace files were visualized using SnapGene Viewer v3.3.3. 
Sequence Reaction             15 μl 
Primer =                                5μl 
DNA (25ng/μl) =                  2μl            
sterile dH
2
0                       8μl 
2.6 Cell line assessment and cell culture  
HeLa cells were used for all functional experimentation during this project.  This cell line 
was chosen based on various necessary criteria including having at least some wild type (WT) 
p53 expression (Figure 4A), an intact homologous repair pathway, a doubling capacity of every 
24 hours (Figure 4B) and epithelial in origin.  While HeLa is a cervical cell line, it is often used 
in cancer studies for these reasons.  Although use of an ovarian cell line is ideal, most immortal 
ovarian cell lines do not have WT p53 activity (Mullany et al., 2015; Fleury et al., 2015) 
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meaning processes downstream of p53 such as DNA damage, cannot be assayed accurately.  
Additionally, the issue of cell line misidentification is common with many “ovarian cell lines” 
(Korch et al., 2012).   All cell lines considered for experimental purposes were sent for 
authentication (Wayne State University at Applied Genomics Technology Center).   The C13 
ovarian cell line obtained from an outside lab was confirmed to be ME-180 cervical cells.  All 
other cell lines were authenticated as being correctly labeled.  
 HeLa cells stably transfected with p.DR-GFP were a kind gift from Dr. Jeffery Parvin of 
Ohio State University. Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (HyClone, GE, Little Chalfont, United Kingdom 
Cat# SH30396.03), NaHCO3 (3.7g/L) 1% penicillin strep (Gibco Life Technologies, Carlsbad, 
CA Cat# 15140-122) and incubated at 37°C 5% CO2.   For passaging, cells were harvested using 
trypsin, and split 1:6.  Freeze downs of aliquots were maintained in a freezing media of 10% 
DMSO, 50% DMEM, 40% FBS and kept at -140°C. 
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Figure 4. Cell line analysis 
A. Western blot for p53 expression in cell lines. p53 expression observed in positive control 
(LJT), ME-180 (originally thought to be C13 ovarian cell line and shown to be cervical of origin 
during authentication) and HeLa.  p53 expression was not detected in hTERT immortalized 
ovarian cells (hTERT OV), SKOV3 cells or TP53-negative control MDAH041.  Abnormal p53 
expression was detected in T80 SV40-Transformed ovarian cells.   B. Microscopy images of 
GFP activity as a proxy for intact HRR in ME-180, and HeLa (see section 2.8 Homologous 
Recombination Repair Assay). Very little GFP activity was observed in T80 cells and none in 
SKOV3 or hTERT immortalized ovarian cells.  
A 
 
 
 
 
B  
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2.7 Protein detection and quantification 
Western blot was employed to assay protein expression and quantification.  First, cells 
were lysed, and proteins solubilized using ice cold RIPA (Radio immunoprecipitation assay 
buffer) supplemented with protease and phosphatase inhibitors.  Protein concentration was 
determined by Bradford assay.  Proteins were then reduced and denatured by adding 4x Laemmli 
buffer plus β-mercaptoethanol to lysates (9:1 ratio respectively), in addition to boiling at 95°C 
for 5 min using thermocycler.  Lysates were stored at -80°C until use for SDS page (sodium 
dodecyl sulfate polyacrylamide gel electrophoresis).  
Next, 50-70μg of whole cell lysate was loaded into each well of a polyacrylamide gel and 
separated by electrophoresis.  Gel percentage varied by size of protein of interest.  Stacking gels 
were prepared at 5%.  7.5% separating gels were used for proteins above 100 kDa and 12% gels 
for proteins below 100 kDa. Following separation, proteins were transferred from the 
polyacrylamide gel to a nitrocellulose membrane by electrical current (250 -350 mA).  Small 
molecular weight proteins were transferred for approximately 1 hour at room temperature (RT), 
large molecular weight proteins 3-4 hours RT or 18 hours overnight at 4°C.  
Membranes were then blocked with 5% bovine serum albumin (BSA) in Tris Buffered 
Saline with Tween 20 (TBST).   Next, membranes were incubated with protein specific 
antibodies at RT for two hours, given three 10 min washings with TBST, incubated with 
secondary antibody for 1 hr. RT, and followed by three more 10 min TBST washings.  Images 
were obtained by LI-COR Biosciences, Lincoln, NE, Odyssey Blot Imager and protein 
expression was quantified using ImageJ software and normalized to appropriate loading control 
(ACTIN for smaller proteins, VINCULIN for large molecular weight proteins).   
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RIPA lysis buffer               80 ml 
1 M Tris-HCL ph. 7.4           4 ml 
1.5 M NaCl                       8 ml  
1% NP40                       800 μl  
5% Na-deoxycholate            4 ml  
.4 M EDTA                       200 μl  
dH20                                   63 ml 
The day of lysis, 10 μl of protease inhibitor cocktail (PIC), sodium pyrophosphate (NaPP), 
sodium fluoride (NaF), sodium orthovanadate (NaV), and phenylmethane sulfonyl fluoride 
(PMSF) was added to every ml of RIPA lysis buffer 
SDS page stacking gel            5%                                
4x stacking buffer             1.25 ml 
Acrylamide/Bis 40:32% .5 ml 
dH
2
0                                      3.25 ml 
10% APS                        25μl 
Temed                                      5 μl 
SDS page separating gel        7.5%    12%                       
2x separating buffer      5 ml   5 ml 
Acrylamide/Bis 40:32% 2.5 ml    3 ml 
dH
2
0                           2.5 ml   2 ml 
10% APS                          100 μl   100 μl 
Temed                                     25 μl   25 μl 
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Transfer buffer:   LMW <100kDA     HMW >100kDA 
TRIS                      6.06 g                 6.06 g 
Glycine                  28.8 g                 28.8 g 
Methanol               400 ml                200 ml 
dH
2
0                   1600 ml              1800 ml 
SDS                         -----                  .01% 
Antibodies for protein detection:  
Protein            Cat#              Manufacturer         
ATM  sc-377293  Santa Cruz Biotechnology, Dallas, TX 
BRCA1 sc-6954  Santa Cruz Biotechnology, Dallas, TX  
BRCA2 sc-28235  Santa Cruz Biotechnology, Dallas, TX 
P53  AHO0152  Invitrogen, Carlsbad, CA   
CHK1  sc-7898  Santa Cruz Biotechnology, Dallas, TX 
CHK2              sc-9064  Santa Cruz Biotechnology, Dallas, TX 
TP53I3 sc-16664  Santa Cruz Biotechnology, Dallas, TX 
FANCM          AB97905   Abcam, Cambridge, United Kingdom 
REC8  sc-15152  Santa Cruz Biotechnology, Dallas, TX 
RAD1  sc-166495  Santa Cruz Biotechnology, Dallas, TX 
RAD51D sc-398819  Santa Cruz Biotechnology, Dallas, TX 
HMMR PA5-21105   Invitrogen, Carlsbad, CA  
MCM4 sc-28317  Santa Cruz Biotechnology, Dallas, TX 
VINCULIN 700062   Invitrogen, Carlsbad, CA    
ACTIN sc-1616  Santa Cruz Biotechnology, Dallas, TX 
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2.8 Homologous recombination repair assay 
The homologous recombination repair assay is a sensitive method developed to measure 
Homologous Recombination Repair (HRR) pathway efficiency following double strand breaks 
(DSB).  HeLa cells were stably transfected with pDR-GFP (direct recombinase green fluorescent 
protein) plasmid and selected with 1.5μg/ml puromycin.  The pDR-GFP plasmid contains two 
inactive GFP alleles; one is inactive due to the presence of an additional sequence that contains 
the 18bp restriction enzyme recognition site for I-SceI, the other is inactive due to a truncating 
mutation.  When a second plasmid encoding the enzyme I-SceI is transiently transfected into 
cells containing this plasmid, the I-SceI restriction site is cleaved creating a DSB. The break can 
only be repaired by the cells’ own endogenous HRR pathway using the second inactive GFP 
allele as a template.  In the case of a working HRR pathway, this leads to the restoration and 
activation of the first GFP allele (Figure 6A). Therefore, the amount of GFP following I-SceI 
DSB induction proxies for the efficiency of the HRR pathway.  This method can accurately assay 
a gene’s involvement in the HRR pathway by measuring the amount of GFP observed after 
siRNA knock down as compared to a scramble siRNA control.  
HRR Assay Protocol: Cells were harvested with trypsin, counted using a hemocytometer 
and reseeded at 40,000 into each well of a 24 well plate.  The next day, media was replaced with 
450 µl serum and antibiotic free media and cells were transfected with I-SceI and siRNA specific 
to the gene of interest using Lipofectamine 3000 (Thermo Fisher, Waltham, MA, Cat# 
L3000015) according to manufacturer’s protocol.  As a negative control, cells were transfected 
with p.cDNA3 empty vector in place of I-SceI to gauge background GFP signal.  As a positive 
control, cells were transfected with scramble siRNA plus I-SceI.  Each condition was performed 
in triplicate.  Forty-eight hours post transient transfection of the I-SceI containing plasmid, cells 
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were visualized for GFP signals using fluorescence microscopy (Olympus 1X71) followed by 
harvesting and analysis by flow cytometry (BD FACSCanto II and BD FACS Diva Software 
v8.0.1, BD Biosciences, San Jose, CA).  Gating procedure was set to select singlets, live (DAPI) 
and GFP (FITC) positive cells (Figure 6B).  A t-test was employed to compare cells transfected 
with a siRNA knockdown of a gene of interest to the siRNA scramble positive control and 
adjusted for background GFP (negative control).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene                       Cat#                        Manufacturer 
Scramble 1027310 Qiagen, Hilden, Germany 
ATM S100299299 Qiagen, Hilden, Germany 
BRCA1 SC-29219 Santa Cruz, Dallas, TX 
BRCA2 S102653434 Qiagen, Hilden, Germany 
CHK1 S100287658 Qiagen, Hilden, Germany 
CHK2 S102224264 Qiagen, Hilden, Germany 
FANCM S104158280 Qiagen, Hilden, Germany 
HMMR S102653196 Qiagen, Hilden, Germany 
MCM4 S100300818    Qiagen, Hilden, Germany 
RAD1 S102653462 Qiagen, Hilden, Germany 
RAD51D S100045094 Qiagen, Hilden, Germany 
REC8 AM16708 Ambion (Invitrogen), Carlsbad, CA 
TP53I3 S100069636 Qiagen, Hilden, Germany 
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Figure 5. Homologous recombination assay A. Schematic of DSB induction during I-SceI 
cleavage and GFP induction by HRR. B. Flow cytometry gating procedure for selection of GFP 
positive cells. 
 
 
 
A. 
 
 
 
 
 
 
B.  
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2.9 Clonogenic survival assay 
The clonogenic survival assay tests the ability of a single cell to form a colony and is a 
well-established method to determine the importance of a gene to cellular survival as well as to 
test cell sensitivity to DNA damaging treatments such as ionizing radiation or chemotherapeutic 
drugs.  Certain drugs are of interest due to their ability to create double strand breaks in DNA. 
Because DSBs are repaired using the HRR pathway, cells efficient in this pathway retain the 
capacity to repair themselves and produce colonies after exposure, while those deficient in HRR 
do not.  Therefore, clonogenic assays involving drug treatments that induce DSBs are an 
excellent tool for identifying genes important to the HRR process, as well as for indicating which 
chemotherapeutic drug may be most appropriate for targeted therapy considering the genomic 
background of certain tumors.   
Clonogenic survival assay protocol: Cells were plated (350,000) in 60-mm tissue culture 
dishes and incubated overnight at 5% CO2 and 37°C.  The next day cells were transfected with 
siRNA using Oligofectamine (Invitrogen, Carlsbad, CA Cat# 12252-011) according to the 
manufacturer’s protocol.  24 hours after transfection, cells were counted, and 100 to 300 cells 
were reseeded in triplicate of a 6 well plate and placed back in incubator.  The following day (48 
hours post siRNA knock down) the media was replaced with serum free media containing a 
DNA damaging reagent such as Cisplatin, Etoposide, Olaparib, or mock control for the duration 
and drug concentration optimized for an IC50 (50% cell growth inhibition) in HeLa.  Cells were 
rinsed twice before adding back fresh media and incubated at 5% CO2 and 37°C for 1.5 weeks 
until colonies had formed (>50 cells per colony).  For fixation and staining, medium was 
removed, and cells washed PBS before adding add 2 ml of acidic acid fixation solution for 5 
minutes followed by 2 ml 0.5% crystal violet solution for 2 hours at room temperature. Once the 
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crystal violet was rinsed off, plates were air-dried at RT for up 24 hours. Colonies were counted 
both by eye and with a colony counter (GELCOUNT, Oxford Optronix, Abingdon, UK).  Plating 
efficiency (PE) was calculated as the number of colonies formed divided by the number of cells 
seeded x 100%.  Survival after drug treatment was determined by calculating the number of 
colonies formed divided by the number of cells seeded x 100%, adjusted for PE.   
2.10 Statistical analysis of functional data 
Statistical analyses of homologous recombination repair and clonogenic assays were 
carried out using R statistical software (version 3.4.1). Prior to the analysis, we checked for and 
did not find outliers (i.e., data points greater than 3 standard deviations from the mean for each 
variable). We next investigated the distribution of replicates for each tested condition (reduction 
in HRR efficiency, plating efficiency, and adjusted survival rate after drug treatment following 
siRNA knockdown). First, we calculated Shapiro-Wilk’s tests, which tests the null hypothesis 
that a sample distribution was drawn from a normally distributed population. Next, we assessed 
skewness and kurtosis for each gene per condition. For small samples (n < 50), z-scores less than 
1.96 for either skewness or kurtosis suggests a normal distribution
14
. We performed 
approximately six replicates for each condition to reduce inflation of Type II error. The overall 
pattern of results generated from the HRR and clonogenic assays indicated normal distributions 
(detailed results available upon request). Paired sample t-tests were then conducted to identify 
mean differences in the survival rates for each siRNA knock down condition and its respective 
scramble siRNA control. 
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CHAPTER 3: RESULTS PART I 
3.1 Clinically actionable variants  
We performed WES on blood DNA from 48 women with a personal history of OVCA 
and determined to be at high risk for inheritance of a germline predisposition mutation, but with 
no known deleterious mutations in BRCA1/BRCA2.  In total, five clearly pathogenic loss of 
function variants were identified (Table 6).  Four were in genes currently featured on newer 
comprehensive HBOC panels; two novel frameshift variants in ATM (c.2503_2507del and 
c.5697_5698insA) and two truncating variants in RAD51D (rs587781756 p.Q171* and 
rs387906843 p.R206*, as well as a pathogenic variant in a non-panel gene, FANCM 
(rs144567652 p.R1931*) previously found to be strongly associated with hereditary risk of 
breast cancer (Peterlongo et al., 2015).  Pathogenic variants in genes with an associated cancer 
risk are considered clinically actionable, meaning a medical intervention, or risk reduction 
measures are available.   
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Table 6. Clinically Actionable Variants are those of high impact (frameshift or stop gain) in 
genes already associated with either breast or ovarian cancer. AA= Amino acid change, 
MAF= Minor allele frequency (ExAC, European non-Finnish) OBS= Number of times variant 
was observed in sample. N/A= Not Available.  All variants listed were confirmed by Sanger 
DNA Sequencing. 
 
 
 
 
 
 
 
 
 
 
Table 6. Clinically Actionable Variants  
ID Gene Consequence AA  dbSNP ID  Variant  MAF OBS 
OCF28-1 ATM FRAMESHIFT CATCTG>C  N/A c.2503_2507del N/A 1 
OCL56 ATM FRAMESHIFT G>GA  N/A c.5697_5698insA N/A 1 
OCJ19 FANCM STOP R1931* rs144567652 c.5713C>T 0.0009 1 
OCH26 RAD51D STOP Q171* rs587781756 c.511C>T N/A 1 
OCK1 RAD51D STOP R206* rs387906843 c.616C>T 0.0001 1 
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ATM (Ataxia Telangiectasia Mutated) codes for a protein kinase important for DNA 
damage recognition and activation of substrates including p53, BRCA1, and other homologous 
recombination repair factors.  Homozygous mutations in ATM cause ataxia-telangiectasia, a rare 
inherited autosomal recessive disorder which affects the immune and nervous systems and leads 
to increased sensitivity to radiation and cancer susceptibility.  Although heterozygous 
ATM mutation carriers do not have ataxia-telangiectasia, they have a 17-52% lifetime risk of 
developing breast cancer (Broeks et al., 2000).  However, despite association of ATM with 
ovarian cancer in recent literature, carriers are not routinely counseled with this information as 
exact risks are unknown.  One patient with an ATM pathogenic variant in our sample (OCF28-1) 
had a family history of liver, lung (n=2) and breast cancer, on the same parental side of the 
family.  The proband herself was first diagnosed with breast cancer at the age of 48 before a 
secondary diagnosis of OVCA at 57 (Figure 6A).  The second carrier of an ATM frameshift 
mutation (OCL56) was diagnosed at 73 and had a family history of OVCA (two additional cases 
besides herself) as well as two cases of breast cancer, all on the maternal side (Figure 6B).   
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Figure 6. ATM LOF variants may lead to increased OVCA risk A. Kindred OCF28-1. 
Proband (indicated with arrow) is positive for ATM c.2503_2507del pathogenic variant. B. 
Kindred OCL56. Proband (indicated with arrow) is positive for ATM c.5697_5698insA 
pathogenic variant. 
 
A.  Kindred OCF28-1 
B.  Kindred OCL56 
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The second gene featuring pathogenic variants in our sample, RAD51D (paralog of 
RAD51), has recently been identified as a moderately penetrant gene in hereditary ovarian cancer 
(Janatova et al., 2015; Thompson et al., 2013; Meindl et al., 2010).  RAD51D forms a complex 
with RAD51B, RAD51C and XRCC2 in order to bind single stranded DNA, a necessary process 
for DNA repair by homologous recombination and is required for RAD51 foci formation upon 
DNA damage induction (Tarsounas, Davies, and West, 2004).  Although rare among familial 
breast cancer patients (Thompson et al., 2013), loss of function variants in RAD51D have been 
associated with a relative risk for OVCA of 6.30. (95% CI 2.86-13.85) (Loveday et al., 2016).  
Two pathogenic nonsense SNPs in RAD51D were discovered in our sample.  One carrier 
(OCH26) was diagnosed at the age of 61 and had a family history of prostate (n=2), breast (n=2) 
and ovarian cancer on her paternal side, while the second carrier (OCK1), diagnosed at 67, had a 
comparatively weak family history with a single diagnosis of colon cancer on her paternal side 
and lung cancer in a maternal aunt.  
In addition, a pathogenic nonsense mutation in a non-panel gene, FANCM (rs144567652, 
p.R1931*) was identified.  This variant has been recently associated with increased risk of breast 
cancer (OR of 3.93) (Peterlongo et al., 2015), warranting contact for further counseling.  
FANCM is the most highly conserved member of the Fanconi Anemia Complementation Group 
(Schwab et al., 2015).  This group is associated with the autosomal recessive genetic disorder, 
Fanconi Anemia, which is characterized by genomic instability, hypersensitivity to DNA damage 
induced by crosslinking agents and substantial increased risk of leukemia and other cancers 
(Bogliolo and Surrallés, 2015).  Other members of the Fanconi Anemia complementation group 
include breast and ovarian cancer-associated genes; RAD51C (FANCO), BRCA1 (FANCS), 
BRCA2 (FANCD1), BRIP1 (FANCJ) and PALB2 (FANCN).  FANCM encodes for an ATP-
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dependent helicase important for the resolution of DNA: RNA hybrids, thus ensuring stability 
with genome duplication (Schwab et al., 2015).  The nonsense variant identified here has been 
shown to affect protein function by also inducing exon skipping (Peterlongo et al., 2015).  The 
carrier (OCJ19) of FANCM rs144567652 was diagnosed with OVCA at 49 years of age and had 
a family history of breast (n=2), multiple myeloma, leukemia, and ovarian, all on the maternal 
side of her family (Figure 7).  
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Figure 7.  Kindred OCJ19. Proband is carrier of FANCM pathogenic variant 
 
 
 
 
 
 
 
 
 
Kindred OCJ19 
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3.2 Variants of unknown clinical significance detected in HBOC panel genes 
 
As most women in our sample were not found to be carriers of a clearly pathogenic 
mutation upon WES, I next sought to identify potentially deleterious variants in HBOC panel 
genes and found that 23 women in the sample (37%) harbored one or more rare and predicted to 
be damaging variants of unknown significance (VUS), in panel genes; ATM, BRCA1, BRCA2, 
CHK2, MHS6, MUTHY, NBN, PALB2, and PMS2 (Table 7).  Analysis of the Human Gene 
Mutation Database (HGMD) (Stenson et al., 2003) revealed that six of these variants are 
annotated as “disease causing” (DM), ten as “possibly disease causing” (DM?) and three as 
“disease associated polymorphism” (DP) in the Human Gene Mutation Database (HGMD) 
(Stenson et al., 2003). 
Carriers of deleterious variants in either ATM, CHK2, PALB2 or NBN are typically 
counseled for their risk of breast cancer, but not ovarian cancer despite associations in current 
literature (Walsh et al., 2011; Thorstenson et al., 2003; Norquist et al., 2015; Lawrenson et al., 
2015).
.
  In addition to the pathogenic ATM frameshift mutations previously discussed, we 
detected an additional six rare and predicted to be damaging missense VUSs in ATM; rs1800054, 
rs138327406, rs28904919, rs1801673, rs56009889, rs35203200.  The ATM variant rs1800054 
(p.S49C) has recently been implicated as associated with a slightly increased risk for breast 
cancer (OR 1.08 (C.I .95-1.22) for heterozygotes, 1.44 (.39-5.32) for homozygotes (Fletcher et 
al., 2010).  ATM variant rs138327406 (p.F1463C MAF= 0.002) is listed as a disease-causing 
mutation in HGMD and was found in three of six women of Ashkenazi Jewish (AJ) descent in 
our sample, always in combination with a second rare polymorphism 266 amino acids apart 
(rs2227922, p.P604S, MAF=0.003) which was predicted to be benign.  These variants were not 
seen in any other women in our sample and linkage data suggests they are not in disequilibrium 
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(r
2 
=0.5, Haploreg v4, CEU).  Therefore, it is suspected that there may be a founder effect 
resulting in the coupled segregation on a single haploblock in the AJ population.  One participant 
(OCG29) was found to have inherited both variants on the same parental allele.  We were not 
able to confirm co-segregation in the other two participants as fresh peripheral blood samples 
were not available to prepare RNA for this analysis.  However, we did find that the unaffected 
daughter of OCD16 was wild type for both variants, suggesting likely co-segregation.   
Similarly, with PALB2, a detected a pair of rare SNPs inherited together, rs45532440 
(p.E672Q MAF= 0.02) and rs45551636 (p.G998E MAF= 0.02) r
2=
0.69, in two unrelated 
individuals (OCH26 and OCE17-2).  PALB2 (partner and localizer of BRCA2), physically 
interacts with BRCA2, and is critical for the localization and stability of BRCA2 in the nucleus. 
Females with monoallelic germline loss of PALB2 have a 2-4 fold increased breast cancer risk 
(Rahman et al., 2010; Erkko et al., 2007).  CHK2 and NBN are also known breast cancer-
associated genes in which we found an interesting VUS in our sample.  Female CHK2 and NBN 
pathogenic mutation carriers are at an increased lifetime risk of developing breast cancer with a 
2-fold for CHK2 and 3-fold for NBN carriers, (The CHEK2 Breast Cancer Case-Control 
Consortium 2004).  Both patients had a family history of breast cancer and the carrier of CHK2 
had a secondary diagnosis of breast cancer.  The p.I232V (rs587780185) variant in CHK2 is 
extremely rare (MAF= 00001).  SIFT and PolyPhen predict this alteration as deleterious and 
probably damaging.  NBN p.I171V (rs61754966) has contradictory annotations among various 
bioinformatics assessment tools, but is annotated as a disease-causing mutation in HGMD.  
Numerous potentially deleterious VUSs in Lynch syndrome and familial adenomatous 
polyposis associated genes were detected in the study sample.  Lynch syndrome (hereditary 
nonpolyposis colorectal cancer), is an autosomal dominant inherited disorder caused by 
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mutations in mismatch repair genes; MLH1, MSH2, MSH6, PMS2, or EPCAM which lead to high 
risk of colorectal cancer (80% lifetime risk) among others, including cancer of the ovaries (10-
15% lifetime risk) and endometrium (71% lifetime risk) (Strafford, 2012).  Skin cancer, in the 
form of Muir-Torre syndrome (a variant of Lynch) is another non-colonic phenotype observed in 
some Lynch families (Bansidhar, 2012; South et al., 2008).  A rare (MAF=0.007), highly 
conserved (GERP=5.35) and predicted as deleterious VUS was found in the Lynch associated 
gene, MHS6 (p.V509A rs63751005).  The carrier of this SNP (OCD16) was diagnosed with 
OVCA at the age of 25, followed by a secondary diagnosis of colon cancer at the age of 65 and 
had a family history of colon and skin cancer as well.  Two patients in the sample were 
heterozygous for very rare missense MUTHY mutations considered to be pathogenic and the 
cause of MYH-associated polyposis (MAP) in homozygote carriers (rs34612342 p.Y179C 
MAF= 0.002 and rs36053993 p.G396D MAF= 0.003).  Although it is possible that a second 
pathogenic MUTHY variant occurred sporadically in the other parental allele, tissue was 
unavailable to detect this change in these patients.  Biallelic mutations in MUTYH have been 
shown to mimic Lynch syndrome by disrupting base excision repair and resulting in a somatic 
loss of function of mismatch repair (Morak et al., 2014).  The carrier of the MUTYH variant, 
rs34612342, (OCE17-2) had a family history of skin and breast cancer and was a carrier of an 
additional VUS in the Lynch gene PMS2.  The carrier of MUTHY rs36053993 (OCQ15) was also 
diagnosed with melanoma and had a family history of colon (n=2) skin (n=2) and ovarian cancer.   
Another conspicuous finding in our sample was the occurrence of a specific BRCA2 
truncating mutation in four unrelated individuals.  The BRCA2 variant p.K3326* (rs11571833) 
results in a 93-amino acid truncation and has a minor allele frequency (MAF) of 0.009 (EXAC 
non-Finnish). The odds ratio of observing this mutation in our sample relative to its MAF in the 
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ExAC cohort is 4.95 (Fisher’s Exact test p-value = 0.01).  It is worth noting that this allele is 
much more frequent in the Finnish population (MAF=.01).  However, even using this more 
frequent MAF as a reference, our test indicates that the allele is still significantly overrepresented 
(p = 0.03, OR = 3.71).  Although the role of BRCA2 has been established in breast and ovarian 
cancer, the K3326* variant is considered to be benign by commercial testing and therefore was 
not identified in the initial BRCA1/BRCA2 screening.  However, recent literature is in 
disagreement with this classification and established that this SNP is a risk factor for lung, oral 
and pancreatic cancers (Akbari et al., 2008; Martin et al., 2005; Rudd et al., 2006) all of which 
were observed in the family histories of the four K3326* carriers; throat (OCP36), lung (OCK1 
and OCF28-1) pancreatic (OCN22), and esophageal cancer (OCN22).  The accepted risk for 
breast cancer in carriers of this SNP is low but significant (p = 0.047, OR 1.53, 95% CI 1.00-
2.34) (Thompson et al. 2015).  Two of the four carriers had a family history of breast cancer, one 
of which had a primary diagnosis of breast cancer prior to ovarian cancer.  Furthermore, analysis 
of the GAME-ON database (>15000 OVCA cases and >30,000 controls) indicates that this SNP 
is also associated with OVCA with a p-value of 2.7x10
-4
 and OR (95% CI) = 1.31 (1.22-9.32) for 
all histologies, and for 8,864 invasive serous OVCA cases versus controls, the p-value was 
7.11x10
-8
 and OR (95% CI) = 1.57 (1.44-1.70).  This data was provided by the Ovarian Cancer 
Association Consortium (OCAC) (http://apps.ccge.medschl.cam.ac.uk/consortia/ocac/).  These 
findings indicate that BRCA2 K3326* is likely a low risk allele in ovarian cancer. 
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Table 7. Rare and predicted to be deleterious/damaging variants of unknown clinical 
significance in sample. AA= Amino acid change, MAF= Minor allele frequency (ExAC, 
European non-Finnish) OBS= Number of times variant was observed in sample. MUT PRED= 
Mutation predictor risk assessment,  LRT= Likely hood Ratio Test for functional predicting of 
mutation,  DEL= deleterious, TOL= Tolerated NEUT= Neutral, MUT TAST= Mutation Taster 
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prediction, DC= Probably Disease Causing, PM= Probably Polymorphism, GERP= Genomic 
Evolutionary Rate Profiling, a score above 2 indicates a highly constrained sequence,  HGMD 
Variant class; DM= Disease causing mutation, DM?= Possible disease causing mutation, DP= 
Disease associated mutation,  N/A= Not Available.  All variants listed were confirmed by Sanger 
DNA Sequencing. 
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3.3 High impact mutations in non-panel candidate genes  
A portion of the missing heritability in OVCA is likely due to risk factors in genes not 
currently featured on testing panels.  The implication of even a highly penetrant mutation would 
be difficult to interpret if rare, even in a mechanistically relevant gene not previously associated 
with the disease.  Despite selecting for patients with high risk of genetic inheritance, half of the 
subjects in our sample were not found to harbor a pathogenic variant, nor a variant of unknown 
significance in any of the 24 panel genes currently tested in HBOC syndromes (Figure 8).  I 
therefore sought to identify rare (MAF ≤ 0.02) mutations in our sample of high functional impact 
(frameshift or stop gain) in candidate genes.  Using DAVID (https://david.ncifcrf.gov/) 
functional annotation and literary searches I compiled a candidate gene list including 115 genes 
involved in DNA repair and/or cell cycle control, the two pathways most commonly associated 
with HBOC, in addition to 64 genes having a disease-causing variant (DM) in HGMD for 
ovarian cancer. A full list of non- panel candidate genes analyzed is provided in methodology 
section (Table 4).   
This analysis uncovered 11 high impact mutations in four cell cycle control genes, 
CHK1, RAD1, TP53I3 (n=2), MCM4, and six DNA repair genes, FANCM, HMMR, POLK, 
POLQ, RAD52 (n=2), and REC8 (Table 8).  Importantly, this analysis resulted in the discovery 
of a clinically actionable pathogenic nonsense variant in FANCM (rs144567652) previously 
discussed.  Most of these non-panel genes are not featured in HGMD, and are they are not 
analyzed during clinical testing.  Therefore, I have provided the mouse phenotype seen in knock-
out studies where possible.  A common phenotypic presentation of many known cancer 
predisposition genes, such as BRCA1/2, includes embryonic lethality in homozygote knockouts 
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and increased cancer incidence in heterozygotes, which are reported in mouse model studies of 
some of these genes (Table 8).   
The frameshift mutation in CHK1 (Checkpoint Kinase 1) is notable because much like 
panel gene CHK2, it encodes for a serine/threonine protein kinase required for checkpoint-
mediated cell cycle arrest and activation of DNA repair HRR.  I also discovered a frameshift 
variant in RAD1, a gene whose protein product functions as part of the 9-1-1 cell cycle 
checkpoint complex to arrest cellular proliferation in the presence of incomplete DNA 
replication or damaged DNA, as well as in MCM4 (Mini-chromosome maintenance complex 
component 4), a highly conserved helicase protein required for genome replication by initiation 
of replication fork formation (Sheu et al., 2014).  The TP53I3 (TP53 inducible protein 3) 
nonsense SNP (rs145078765 p. S252* MAF= 0.0009) is also of great interest as it was observed 
in two unrelated individuals in our sample.  TP53I3 is an oxidoreductase-like protein and an 
inducer of reactive oxygen species (ROS), that is transcriptionally activated by the tumor 
suppressor P53 and likely to be involved in P53-mediated apoptosis (Zhang et al., 2015).  
Among DNA repair genes, I observed high impact mutations in those encoding DNA 
polymerases, POLK (c.1336del), a translesion polymerase that initiates the continuation of 
replication through DNA lesions in damaged DNA, and POLQ (p.Q2513* rs148626322), a gene 
associated with micro homology-mediated end-joining pathway (MMEJ), both in the same 
patient.  I also identified truncating variants in chromatid cohesion REC8, whose protein product 
binds sister chromatids during meiosis, and HMMR (hyaluronan mediated mobility receptor), 
which encodes for a cell motility protein that forms a complex with tumor suppressors BRCA1 
and BRCA2.  Common missense variations in HMMR have been shown to modify the penetrance 
of breast cancer risk in BRCA1 pathogenic mutation carriers (Maxwell et al., 2011).  
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Furthermore, two RAD52 truncating SNPs; rs4987207 p.S346* and rs4987208 p.Y415* were 
discovered.  RAD52 mediates complementary ssDNA annealing and recruits RAD51 
recombinase to promote recombination and HRR.  However, the RAD52 truncating variants 
observed in our sample had previously been found to lack an association with OVCA or breast 
cancer (J. Han et al., 2002).  
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Figure 8. Summary of variant findings amongst our 48 subjects of high risk for 
genetic inheritance of OVCA.
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Table 8. High Impact Mutations in DNA repair and Cell Cycle Control Genes, not 
Featured on HBOC Testing Panels. Rare and high impact variants (frameshift or stop gain) in 
sample found in DNA repair or cell cycle control genes not currently known to associate with 
breast or ovarian cancer.  MAF=Minor Allele Frequency in Non-Finish Europeans (ExAC).  
Mouse Phenotype= Available phenotypic information on homozygote (-/-) or heterozygote (+/-) 
mouse knock out models. Ovary expression data RPKM (reads per kilobase per million) obtained 
by https://gtexportal.org. *For reference, OVCA genes BRCA1=.6, BRCA2= .095, RAD51D= 4.  
All variants listed were confirmed by Sanger DNA Sequencing. 
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3.4 BRCA2 p.K3326* truncation as a possible modifier of penetrance  
The prevalence of the BRCA2 K3326* variant (Figure 9A) in our sample, along with the 
evidence of an association with lung, aero digestive, and pancreatic cancer (Akbari et al. 2008; 
Martin et al. 2005; Rudd et al. 2006) indicate that this variant may be of minimal risk when 
inherited alone but could act as a modifier of penetrance to a secondary more deleterious 
mutation.  A portion of the missing heritability in OVCA is likely due to this type of polygenic 
inheritance.  This possibility led to the investigation of other putative pathogenic variants that 
each of the four carriers had inherited in addition to BRCA2 p.K3326* (Table 4).  I therefore 
looked for additional rare, and moderate or high impact variants in either HBOC panel genes or 
candidate genes (involved in DNA repair/cell cycle and with cancer associations in HGMD) 
amongst the four BRCA2 K3326* carriers.  A complete list of rare and predicted to be damaging 
variants of moderate impact in cell cycle and DNA repair genes is available in the appendix 
(Table 12).  
 In analyzing relevant candidate genes, I identified two patients who along with K3326* 
were carriers of an additional, clearly pathogenic variant; a RAD51D nonsense mutation (OCK1) 
and ATM frameshift mutation (OCF28-1).  This observation is interesting because BRCA2 
interacts with the RAD51 paralogs and a BRCA2/RAD51D double knockdown leads to a greater 
loss of cellular viability (Jensen et al., 2013).  The carrier of both the ATM frameshift and 
BRCA2 K3326* variants developed both breast and ovarian cancer.  Sequencing of some of her 
immediate family members at these loci determined that both variants were inherited from her 
father, who died of liver cancer and a twin sibling and paternal grandfather of the patient, both of 
whom died of lung cancer (a disease associated with this SNP), but whose genotypes are not 
available (Yufei Wang et al., 2015).  A second female sibling of this patient had inherited the 
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ATM frameshift but not the BRCA2 K3326* variant and developed breast cancer at the age of 46 
(Figure 9B).  
66 
 
 
 
 
A. 
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Figure 9. BRCA2 K3326* may be a modifier of penetrance A. BRCA2 protein schematic 
depicting site of truncation p.K3326* variant.  Variant occurs at the C-Terminus (red) which 
occurs in a RAD51 binding domain and site of CDK2 phosphorylation. B. OCF28 kindred. Arrow 
indicates patient OCF28-1 Kindred of proband (arrow) with p.K3326* plus pathogenic ATM 
frameshift shows inheritance of both alleles from an affected father.  
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Carriers of BRCA2 p.K3326* and additional variants of interest 
Patient 
ID 
Gene Consequence Amino Acids dbSNP ID   Variant MAF HGMD cancer 
phenotype  
SIFT PolyPhen 
OCF28-1 ATM FRAMESHIFT CATCTG>C 
Exon 13 
N/A c.2503_2507del N/A Breast/Ovarian  N/A N/A 
BRCA2 STOP K3326* rs11571833 c.9976A>T 0.009 Breast/Ovarian N/A N/A 
PALLD MISSENSE R303S rs138897963 c.909A>T 0.001 Pancreatic TOL Probably 
Damaging 
OCK1 ATM MISSENSE F1463C rs138327406 c.4388T>G 0.002 Breast/Ovarian DEL Probably 
Damaging 
BRCA2 STOP K3326* rs11571833 c.9976A>T 0.009 Breast/Ovarian N/A N/A 
ERCC6 MISSENSE M713V rs201486862 c.2137A>G 0.00001 Basal cell carcinoma, 
Cockayne syndrome,  
DEL Benign 
HMMR STOP E352* rs146791423 c.1054G>T 0.003 None N/A N/A 
RAD51D STOP R206* rs387906843 c.616C>T 0.00001 Breast/Ovarian N/A N/A 
RECQL MISSENSE C321Y rs150889040 c.962G>A 0.00001 Breast N/A Probably 
Damaging  
OCN22 BRCA2 STOP K3326* rs11571833 c.9976A>T 0.009 Breast/Ovarian N/A N/A 
BUB1B MISSENSE E409D rs28989188 c.1227A>C 0.0004 Gastrointestinal TOL Probably 
Damaging 
OCP36 BRCA2 STOP K3326* rs11571833 c.9976A>T 0.009 Breast/Ovarian N/A N/A 
AXIN1 MISSENSE V340M rs143974067 c.1018G>A 0.00004 Colorectal adenoma DEL Probably 
Damaging 
 
Table 9. Additional VUSs in carriers of BRCA2 K3326* Rare and predicted to be 
deleterious/damaging variants (SIFT/PolyPhen-2) found in carriers of BRCA2 p.K3326*. MAF= 
Minor allele frequency (ExAC, European non-Finnish) OBS= Number of times variant was 
observed in sample, DEL= deleterious TOL= Tolerated, N/A= Not Available.  All variants listed 
were confirmed by Sanger DNA Sequencing. 
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CHAPTER 4: DISCUSSION PART I 
We performed WES on 48 women with OVCA and suspected to have an inherited cancer   
predisposition, yet, were previously tested and found negative for known pathogenic mutations 
in either BRCA1 or BRCA2.  In doing so, we discovered pathogenic variants in ATM (n=2) and 
FANCM (n=1), genes currently associated with breast cancer but not OVCA, as well as in a gene 
recently implicated in hereditary ovarian cancer risk, RAD51D (n=2).  These findings suggest 
that carriers of ATM and FANCM pathogenic mutations are possibly at elevated risk of 
developing OVCA as well as breast cancer and that the underling genetics of these two cancers 
may overlap more than previously believed.  Available expression data via GTEx Portal (Broad 
Institute) indicate both genes have higher RPKM (reads per kilobase per million) scores in ovary 
tissue versus breast; ATM =3.6 breast, 8.7 ovary and FANCM =.89 breast, 1.1 ovary 
(https://gtexportal.org) indicating that these genes are expressed in ovarian cells.  Furthermore, 
the results from WES indicate that there is clinical value of resequencing BRCA1/2 negative 
individuals that fit current NCCN guidelines and whose genetic risk was assessed before the era 
of multi-gene panel testing.   
4.1 WES highlights three likely sources of missing heritability  
The majority of the high risk OVCA participants in our WES sample set did not harbor a 
known clinically actionable cancer predisposing mutation upon reanalysis with whole exome 
sequencing even in known panel genes, emphasizing the current challenge for genetic testing and 
counseling in clinical cancer care.  Despite the large heritable component to OVCA, the majority 
of underlying genetic risk remains unexplained (Pharoah et al., 2013).  Although many novel 
putative risk loci were discovered, most are rare or private familial missense mutations of 
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unknown clinical significance and not found in the published literature.  The rarity of these 
variants also means that they would not be identifiable in GWAS studies.   
4.1.1 Variants of Unknown Significance 
Many high-risk women who undergo testing for HBOC are found to be carriers of one or 
more “variants of unknown significance” (VUSs), (Domchek and Weber, 2008) a rare, generally 
missense mutations, unannotated in their consequence to disease risk rather than a clearly 
pathogenic variant.  Although the functional consequence of high impact variants such as 
nonsense and frameshift mutations are straightforward to interpret, missense mutations which 
result in single amino acid substitutions are of ambiguous significance.  I observed suspicious 
missense VUSs in HBOC panel genes employing well-accepted bioinformatics techniques: 
BRCA1, BRCA2, CHK2, MUTHY, MHS6, NBN, PMS2, and most notably in ATM and PALB2.  
Overall, such suspicious variants in 23 of our 48 test subjects were uncovered.    
The ability to assess VUSs is crucial to closing the gap in unexplained heritability while 
aiding in more informed clinical decisions.  A common approach to implicating a VUS is by 
linkage analysis, whereby the causal mutation is expected to segregate with the disease in one or 
more families.  Unfortunately, DNA samples from other affected and non-affected family 
members are generally not often available.  A linkage analysis is also not ideal for low to 
moderate risk factors because these variants are not highly penetrant.  Bioinformatic prediction 
tools for variant consequence on protein function, such as SIFT and PolyPhen, are very useful 
for prioritizing variants for follow up.  However, in silico assessment tools such as these often 
contradict each other and are not considered to have enough sensitivity and specificity to inform 
clinical decisions (Richards et al., 2015).  Despite the advent of detailed guidelines for variant 
interpretation, many variants in ClinVar list numerous testing facility submissions with 
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conflicting interpretations of pathogenicity.  Thus, the vast majority of single nucleotide 
polymorphisms (SNPs) in cancer-relevant genes remain unannotated as to whether the change is 
deleterious to protein function and potentially disease causing.   
4.1.2 Polygenic risk loci  
Further complicating this issue is that under a polygenic model for hereditary cancer risk, 
carriers of multiple low penetrant genetic variants could be at high risk (Johnson et al., 2007), 
meaning much of the unexplained heritability in OVCA may be due to more than one genetic 
risk factor that, when inherited together, have an additive or synergistic effect.  One variant in 
BRCA2 (p.K3326*) stood out as a possible modifier of penetrance due to an almost five-fold 
increased occurrence over expected and the observation that two of the four women carrying this 
SNP also had a pathogenic mutation of moderate effect in a second low penetrance gene 
involved in DNA repair, (ATM and RAD51D).  This SNP results in a 93-amino acid truncation 
and is reported as benign according to genetic testing services, mostly due to weak disease co-
segregation in familial studies.  This assessment has been questioned in recent literature due to 
its association with other cancers.  Functional data have suggested that K3326* acts similar to 
wild type BRCA2 for recombination repair and MMC sensitivity (K. Wu et al., 2005).  However, 
the K3326* truncation is located at the C-terminus of the BRCA2 protein (exon 27), and deletion 
of this domain has been shown to result in reduced cellular response to stalled and collapsed 
replication forks, (T. M. Kim et al. 2014) hypersensitivity to gamma-radiation and premature 
senescence (Morimatsu, Donoho, and Hasty, 1998).  Additional evidence in the literature along 
with our findings suggest the possibility that this variant that may be of minimal effect alone but 
enhances the penetrance of another moderately penetrant inherited variant in the same functional 
pathway.  This would explain the weak genotype to phenotype correlation with this variant as 
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well as the observation that this variant has been found in-trans with other pathogenic BRCA2 
mutations, without causing Fanconi Anemia.  Due to our small sample set, the occurrence of this 
SNP with additional moderate pathogenic mutations in the same pathway could be by chance.   
However, in agreement with the hypothesis of a role as a possible modifier of penetrance, the 
BRCA2 K3326* truncation is found in The Cancer Genome Atlas (TCGA) database three times, 
each in OVCA patients who are all also carriers of pathogenic genetic variants; (TCGA-24-1562-
01 with an NF1 frameshift, aTCGA-13-1512-01 and TCGA-23-1026-01 with BRCA1 frameshift 
mutations (http://cancergenome.nih.gov).  
4.1.3 Novel genes yet to be implicated in risk association studies 
It is likely additional risk genes exist that, when mutated, predispose to breast and/or 
ovarian cancer, but have yet to be implicated due to their rarity or low penetrance.  In my attempt 
to discover novel OVCA predisposition genes, I chose to focus on genes involved in DNA repair 
or cell cycle control as these two dynamic and interrelated pathways are crucial to genomic 
stability and are the most mutated pathways in hereditary breast and ovarian cancers.  In doing 
so, I discovered 11 high impact mutations in genes that are not featured on current HBOC risk 
assessment panels (CHK1, FANCM, HMMR, MCM4, POLK, POLQ, RAD1, RAD52, REC8, and 
TP53I3) but have very similar or overlapping functions to those genes on commercial panels.  
The finding of a pathogenic variant in FANCM during this specific analysis is promising as it 
affirms the candidate gene rationale and marks the first known case of a FANCM deleterious 
variant in an ovarian cancer patient.  Of the eleven variants discovered in this analysis, five were 
novel.  The rarity of these high impact variants is likely due to the essential natures of the DNA 
repair and cell cycle pathways.  Knock out mouse model studies of CHK1, MCM4, and RAD1 all 
show embryonic lethality in homozygous null mice and increased cancer incidence in 
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heterozygotes (Table 8), similarly to BRCA1/2, which makes them compelling and worthy of 
following up with functional studies.  This study is the first of its kind to describe these germline 
loss of function variants in ovarian cancer patients with inherited risk.  Further work should 
include analyzing genes in other cancer related pathways since risk loci may also occur in 
mechanisms not involved in DNA repair or cell cycle control. 
4.2 Functional assessment is necessary to implicate novel genetic loci identified by 
bioinformatics tools 
One key challenge facing genetic testing and counseling in clinical cancer care is the 
functional significance of VUSs in cancer-associated genes as well as loss of function variants in 
candidate risk genes.  This information is necessary to provide genetics professionals with 
guidance for better informed patient risk evaluation, risk reduction strategies and possibly 
improved therapeutic modalities.  While bioinformatics tools for assessment are useful for 
variant filtering purposes, they are not sensitive enough for clinical decisions.  Ideally, missense 
variants predicted by bioinformatics algorithms to be ‘pathogenic’ or ‘likely pathogenic’ and 
novel candidate genes found with high impact mutations would be functionally tested using 
sensitive and specific assays that add to computational evidence for clinical insights.  Because a 
single low-to-moderately deleterious mutation may appear inconsequential alone but could 
modify the penetrance of a deleterious mutation in the same pathway, combining the risk of 
multiple genetic variants may also lead to better risk assessment.   
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CHAPTER 5: RESULTS PART II 
Analysis of WES data from 48 high risk women with OVCA revealed 11 loss of function 
variants in genes not already implicated in hereditary OVCA risk, but whose protein products are 
involved in DNA repair and/or cell cycle control, the two most commonly mutated pathways in 
HBOC.   Because hereditary OVCA is rare, displays variable penetrance, and has a high degree 
of underlying genetic heterogeneity, the implication of a novel gene, especially of high 
penetrance, is unlikely to occur through case control associative studies.  Therefore, I chose to 
functionally assess various candidate genes found mutated in our cohort.  Specifically, FANCM, 
CHK1, MCM4, RAD1, and REC8 were of interest due to their conservation and cancer-
associated mouse model phenotype which includes embryonic lethality in homozygote 
knockouts and increased cancer incidence in heterozygotes.  I was particularly interested in 
TP53I3 because a very rare high impact mutation in this gene occurred twice in our cohort in 
unrelated individuals.  Also there was very limited functional data and no mouse model 
phenotype in the literature.  Finally, HMMR was also chosen because it has been shown to form 
a complex with BRCA1/BRCA2 and common missense variations in this gene have been shown 
to modify the penetrance of breast cancer risk in BRCA1 pathogenic mutation carriers (Maxwell 
et al., 2011).  
Genes chosen as positive controls for functional analyses include HBOC risk genes 
BRCA1 and BRCA2 (high risk) as well as ATM, CHK1, RAD51D (moderate risk).  The choice of 
multiple positive controls with both high and moderate penetrance was to gauge the sensitivity of 
the assays employed for both highly and moderately penetrant genes as well as to determine 
whether they could distinguish between a gene of high penetrance and one of moderate 
penetrance. Two highly sensitive assays were employed to measure involvement in homologous 
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recombination repair (HRR) and sensitivity to DNA damage induction; the HRR Assay and 
clonogenic survival assay, respectively (see Materials and Methods sections 2.8 and 2.9).  The 
HRR assay quantifies the efficiency of the cell’s endogenous HRR pathway by inducing double 
strand DNA breaks (DSB) into cells with a non-functional and stably transfected GFP allele.  
The GFP allele will only become active once the DSB repair has occurred, therefore the amount 
of GFP induction proxies for the efficiency of the HRR pathway.  This method accurately assays 
a gene’s involvement in the HRR pathway by measuring the amount of GFP observed after 
siRNA knock down as compared to a scramble siRNA control after DSB induction.  The 
clonogenic survival assay is a commonly applied tool to assay a gene’s involvement in cell 
survival as well as to measure drug cytotoxicity.  It is often used to determine the effectiveness 
of chemotherapeutic reagents under various tumor genetic profiles.  All functional analyses were 
carried out with the use of small inhibitory RNAs (siRNA), which interfere with the expression 
of a targeted gene by preventing mRNA translation.  Knock downs achieved by siRNA were 
verified by western blotting technique described in Materials and Methods section 2.7 “Protein 
Detection and Quantification.”  These blots are featured in the appendix of this manuscript.  
5.1 Knock down of various candidate genes found mutated in cohort lead to reduced 
homologous recombination repair efficiency 
Using the HRR protocol described in section 2.8, I compared the amount of GFP 
observed 48 hours after I-SCEI DSB induction among cells with siRNA knockdown of both 
candidate and control genes to cells with no knock down (scramble siRNA control).  All 
conditions were adjusted for a negative control background (empty plasmid in place of I-SCEI 
plus scramble siRNA).  Five to six replicates represent each condition to reduce inflation of Type 
II error.  siRNA knock down of panel genes tested (BRCA1, BRCA2, ATM, CHK2 and RAD51D), 
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led to a significant decrease in HRR efficiency after siRNA knock down.  Notably, knock down 
of BRCA1 and BRCA2 led to the highest reduction in HRR efficiency (approximately 70% and 
89% less compared to scramble control respectively (reported as mean difference MD)) while 
ATM, CHK2 and RAD51D knock down led to moderate reduction in HRR efficiency (45% 27%, 
and 35% reduction respectively), consistent with their roles as moderately penetrant genes.  
siRNA depletion of candidate genes REC8, TP53I3, CHK1 and FANCM all lead to a significant 
reduction in HRR.  The greatest reduction amongst candidate genes was observed with CHK1 
which was similar to BRCA1 and lead to a reduction of 69.2% (p=<0.001).  The next largest 
reduction in HRR efficiency was observed with FANCM, (MD= 54.1, p=<0.001).  Knock down 
of TP53I3 led to a reduction of 33% (p=0.001) and REC8 with a modest reduction of 14.8% 
(p=0.001).  siRNA depletion of RAD1 did not lead to a decrease in HRR efficiency but seemed 
to trend towards an increase. While this is not statistically significant, biologically it would make 
sense since RAD1 is believed to play a role in microhomology-mediated end joining (MMEJ) for 
the repair of ionizing radiation and chemicals that induce DSBs (Ma et al., 2003).  Therefore, 
cells depleted of RAD1 may be more reliant on the HRR pathway for DSB repair. One study has 
shown RAD1 as indispensable to microhomology-mediated end joining (MMEJ) for the repair of 
ionizing radiation and chemicals that induce DSBs (Ma et al. 2003). 
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Figure 10. HRR efficiency after siRNA knockdown.  M = Mean % of GFP; SD = Standard 
deviation; MD = mean difference as compared to scramble control.  t = statistical test for mean 
difference; * p<0.05; ** p<0.01; ***p<0.001; p-values in bold are significant. Data normalized 
to negative control for GFP background signal and positive control for GFP induction.  
  Gene M SD MD t p 
  Scramble 97.4 2.58 --- --- --- 
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a
n
el
 
ATM 51.9 13.43 -45.5 6.72 0.006 
BRCA1 27.5 8.32 -69.9 21.45 0.000 
BRCA2 8.6 5.02 -88.8 39.97 0.000 
CHK2 70.3 9.96 -27.1 5.98 0.003 
RAD51D 62.8 12.61 -34.7 5.452 0.011 
  
  
  
  
  
  
 N
o
n
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a
n
el
 
FANCM 43.3 6.68 -54.1 21.53 0.000 
CHEK1 28.2 14.04 -69.2 11.95 0.000 
RAD1 108.7 7.57 11.2 -2.52 0.119 
REC8 82.6 5.68 -14.8 6.40 0.000 
TP53I3 64.4 13.55 -33.0 7.55 0.000 
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5.2 Knock down of RAD1, CHK1 or FANCM lead to a decrease in cellular viability  
One key genetic mechanism in the process of tumorigenesis is the loss of heterozygosity 
(LOH) at tumor suppressor loci leading to the “inactivation” of genes required for the regulation 
of cell growth and differentiation (Ryland et al., 2015).  Functional loss of genes essential for 
cellular viability is known to encourage LOH (Yuxun Wang et al., 2010) and is associated with 
increased cancer risk.  For instance, ovarian breast cancer risk genes BRCA1 or BRCA2 are both 
involved in cellular viability.  To identify which of the candidate genes are also involved with 
cellular viability, I compared the clonogenic survival of cells after siRNA knockdown of 
candidate and control genes to a scramble siRNA control (Figure 11).  Five to six replicates 
represent each condition repeated to reduce inflation of Type II error.  Among panel genes 
tested, siRNA knock down of either ATM, BRCA1 or BRCA2 lead to significant a loss of 
clonogenic survival. There was no loss of cellular viability observed for panel genes CHK2 or 
RAD51D.  For candidate gene CHK1, there was a loss of clonogenic survival similar to BRCA1 
and BRCA2 (CHK1 = mean survival of 13.8%, BRCA1 = mean survival of 16.5%, BRCA2 = 
mean survival of 8.8%).  In addition, siRNA knock down of candidate gene RAD1 led to a 
reduction in clonogenic survival that was similar to that observed with ATM (mean survival of 
23.3% vs 29.6% respectively). Most interestingly, siRNA depletion of FANCM led to the 
greatest loss in clonogenic survival with a mean plating efficiency of just 2%.  
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Figure 11. Plating efficiency after siRNA knock down. M = Mean % survival; SD = Standard 
deviation; MD = mean difference as compared to scramble control.  t = statistical test for mean 
difference; * p<0.05; ** p<0.01; ***p<0.001; p-values in bold are significant. 
     
  Gene M SD MD t p 
  Scramble 42.4 5.44 --- --- --- 
P
a
n
el
 
ATM 29.6 10.06 -12.8 -2.55 0.044 
BRCA1 16.5 3.54 -25.9 -9.78 0.000 
BRCA2 8.8 6.59 -33.6 -9.62 0.000 
CHK2 35.7 5.54 -6.7 -2.12 0.060 
RAD51D 37.7 11.94 -4.7 -0.88 0.406 
N
o
n
-P
a
n
el
 
FANCM 2.1 1.83 -40.3 -17.2 0.000 
CHK1 13.8 6.37 -28.6 -8.37 0.000 
HMMR 43.8 17.09 1.4 0.19 0.855 
MCM4 40.0 7.87 -2.4 -0.61 0.554 
RAD1 23.3 8.82 -19.1 -4.51 0.002 
REC8 42.6 4.78 0.2 0.06 0.952 
TP53I3 37.8 8.98 -4.6 -1.07 0.315 
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5.3 Cells deficient in CHK1, RAD1, TP53I3 or REC8 display significant sensitivity 
to DNA damage 
Genomic stability is directly related to a cell’s DNA repair efficiency.  Cells deficient in 
DNA repair mechanisms display greater sensitivity to DNA damaging reagents.  
Chemotherapeutic drugs; Cisplatin, Etoposide, and Olaparib specifically exploit this 
vulnerability and cells deficient in tumor suppressor genes BRCA1 or BRCA2 are especially 
sensitive to these reagents.  To assess whether, and to what extent, any of the candidate genes are 
involved in DNA repair and genomic integrity, I compared the clonogenic survival of cells with 
targeted siRNA depletion of candidate and panel genes to a scramble siRNA followed by 
exposure to Cisplatin, Etoposide, or Olaparib. These three reagents where chosen due to their 
different mechanisms regarding DNA damage and in relevance to current OVCA therapies. Cells 
were exposed to the drugs 48 hours post siRNA knock down, when the targeted depletion is 
greatest. Drug concentration and exposure were determined by optimizing for an IC50, which for 
the purposes of these experiments, is the concentration required for 50% cytotoxicity in a 
scramble siRNA knock down control.  The IC50 treatment exposure for each reagent was as 
follows: Cisplatin= 2 M for 2 hours, Etoposide= 10 M for 4 hours, and Olaparib 10 M for 4 
hours.  The clonogenic survival after drug exposure for each condition was adjusted to the 
plating efficiency observed with the same siRNA knock-down and without drug exposure.  Five 
to six replicates represent each condition repeat to reduce inflation of Type II error.  The 
assessment of candidate gene FANCM to these reagents was not possible due to the extreme loss 
of cellular viability that occurred after siRNA depletion. 
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5.3.1 Cells deficient in CHK1, RAD1 or TP53I3 display increased sensitivity to Cisplatin 
Cisplatin generates interstrand cross links (ICLs) which are covalent bonds between both 
strands of a DNA duplex.  ICLs inhibit crucial processes such as DNA replication, ultimately 
leading to chromosomal instability.  ICLs are repaired by HRR and thus, cells deficient in this 
pathway are highly sensitive to DNA-damaging agents such as Cisplatin.  As expected, all panel 
genes included in this assay (BRCA1, BRCA2, ATM, CHK2, and RAD51D) were demonstrated to 
be involved in HRR and ICL repair as targeted siRNA against their respective mRNA products 
led to significantly increased cytotoxicity with Cisplatin exposure (Figure 12A, Table 10). 
Specifically, loss of BRCA1 or BRCA2 leads to the most sensitivity, each with a mean 
difference of approximately 40% increased cytotoxicity as compared to the scramble control. 
This observation is consistent with their status as highly penetrant in cancer susceptibility when 
mutated.  Cells with knock down of candidate genes: CHK1, RAD1, or TP53I3 also displayed 
significantly increased sensitivity to cisplatin exposure equal of greater to that observed in the 
moderately penetrant panel genes ATM, RAD51D and CHK2 (Figure 12A, Table 10).  Loss of 
RAD1 led to the most sensitivity observed amongst candidate genes with a mean viability of 
18.3% which is a 33% increased cytotoxicity as compared to the scramble control (p=<0.001). 
Depletion of CHK1 and TP53I3 both led to a mean increase in cisplatin cytotoxicity of 
approximately 27% (p=<0.001, p=<0.001 respectively.)  There was no increased cisplatin 
cytotoxicity observed after knock-down of REC8, HMMR or MCM4. 
5.3.2 Cells deficient in CHK1, REC8 or RAD1 display increased sensitivity Etoposide  
Etoposide is a topoisomerase II (topoII) alpha inhibitor approved for clinical use as a 
chemotherapeutic reagent in platinum resistant OVCA.  Topoisomerase II enzymes are 
responsible for simultaneously cleaving both stands of the DNA double helix for the 
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management of entangled and supercoiled DNA. These enzymes are essential for DNA 
replication.  Inhibition of topoII by Etoposide prevents the re-ligation of cleaved DNA and 
therefore leads to DNA DSBs.  Etoposide also results in single-strand DNA breaks (SSBs), since 
it prevents the re-ligation of the stands independently of each other (Yang et al. 2009).  BRCA1 
and BRCA2 deficient cells have been described as sensitive to etoposide treatment 
(Treszezamsky et al., 2007).  Consistent with these reports, both BRCA1 and BRCA2 deficient 
cells displayed significant sensitivity to Etoposide in this assay.  Knock down of CHK2 or 
RAD51D also led to increased Etoposide sensitivity (with approximately 30% and 14% increased 
cytotoxicity respectively).  Among non-panel candidate genes, CHK1, RAD1 and REC8 knock 
down all resulted in increased cytotoxicity in response to Etoposide.  CHK1 deficient cells 
displayed a mean survival of 34.9% (p=0.024), RAD1 24.5% (p=<0.000) and REC8 35.4% 
(p=0.018), which is an increase of approximately 14%, 24% and 13% in cytotoxicity versus the 
scramble control respectively. (Figure 12B) 
5.3.3 Cytotoxicity to Olaparib is specific to BRCA1 and BRCA2 deficient cells.  
Olaparib is a PolyADP-ribose polymerase (PARP) inhibitor approved for clinical as an 
adjunct to platinum-based therapies in patients with BRCA1 or BRCA2 deficiencies.  Tumor cells 
with mutant BRCA1 and/or BRCA2 have demonstrated to be up to 1000 times more sensitive to 
PARP inhibitors as compared to WT cells (Farmer et al. 2005; Bryant et al. 2005).  Cancer cells 
deficient in HRR are more dependent on the PARP proteins which are involved in ssDNA break 
repair by Base Excision Repair (BER). Inhibiting this pathway leads to synthetic lethality as the 
cells loses its back up mechanism to repair DNA.  In clinical trials, the use of PARP inhibitors 
have shown to improve the progression-free survival when added to the treatment of women with 
breast or ovarian cancer responsive to platinum, which induces DSBs (Robson et al., 2017; 
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Ledermann, 2016; Evans and Matulonis, 2017).  Olaparib used as a monotherapy has shown to 
be effective in patients with germline BRCA1/2 mutation and advanced cancer (G. Kim et al. 
2015; Kaufman et al., 2015).   In this experiment, cells were treated with Olaparib in the absence 
of cisplatin and increased cytotoxicity was specific to BRCA1 and BRCA2 deficient cells 
(Figure 12C, Table 10).  ATM, CHK2 and RAD51D panel genes have demonstrated a less 
prominent role in HRR as compared to BRCA1 or BRCA2 (Figure 10).  This observation may 
indicate that sensitivity to Olaparib requires a heavier reliance on the BER pathway. It is also 
possible that deficiency of ATM, CHK2 or RAD51D would lead to increased Olaparib sensitivity, 
but only in conjunction with platinum-based therapy.   
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Figure 12. Clonogenic survival rates after drug exposure by siRNA knock down A. Cell 
Survival after exposure to Cisplatin by siRNA knockdown. All values adjusted to mean plating 
efficiency after siRNA knockdown alone.  B. Cell Survival after exposure to Etoposide by 
siRNA knockdown.  All values adjusted to mean plating efficiency after siRNA knockdown 
alone.  C. Cell Survival after exposure to Olaparib by siRNA knockdown.  All values adjusted to 
mean plating efficiency after siRNA knockdown alone.  * p<0.05; ** p<0.01; ***p<0.001. 
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Table 10. Statistical data for clonogenic survival rates after Cisplatin, Etoposide and 
Olaparib treatment by siRNA knockdown. M = Mean % survival; SD = Standard deviation; 
MD = mean difference as compared to scramble control.  t = statistical test for mean difference; 
* p<0.05; ** p<0.01; ***p<0.001; p-values in bold are significant. 
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5.4. Estimating penetrance through a 2-dimensional model of cell viability and DNA 
sensitivity 
Most cancer-associated risk loci have incomplete penetrance.  The penetrance of a 
pathogenic variant is determined by its associated lifetime risk with disease.  Genes are often 
described as having low, moderate, or high penetrance based on the lifetime risk associated with 
a loss of function variant. BRCA1 is the most highly penetrant gene in hereditary breast and 
ovarian cancer syndrome with an 80% lifetime risk of breast cancer and 50% risk of OVCA for 
LOF variants.  Accurate estimates of genetic penetrance are necessary to inform clinical 
decisions.  Therefore, it would be optimal to evaluate novel risk genes in a manner that would 
provide an indication of penetrance employing a functional test.   
The two genes with the highest known penetrance for HBOC in the literature, BRCA1 
and BRCA2, are important to both cellular viability and DNA repair.  Loss of function of either 
leads to a profound reduction of cellular viability, and increased sensitivity to DNA damaging 
reagents as observed in the various functional assays employed in this study.  Functional 
depletion of genes that are moderate in their penetrance, such as ATM, RAD51D and CHK2, lead 
to more moderately increased DNA damage sensitivity as compared to BRCA1/BRCA2, and may 
or may not impact cell viability in the absence of a cytotoxic reagent.  Because cell viability and 
DNA damage sensitivity can be observed independently of each other yet are both phenotypes of 
a BRCA-like tumor suppressor gene, plotting genes using a two-dimensional graph based on 
these phenotypical outcomes may lead to a separate geographical clustering of high and 
moderately penetrant genes in HBOC risk.  By plotting genes with known penetrance, we can 
assess the potential of this method.  If accurate, we can then use this scale to estimate the likely 
risk/penetrance of candidate risk genes that act as a tumor suppressor in a BRCA-like manner.  
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5.4.1 Plotting panel genes based on cell viability and DNA damage sensitivity after siRNA 
knock down correctly differentiates between moderate and high penetrance 
The three different chemotherapeutic drugs (Cisplatin, Etoposide and Olaparib) employed 
for the clonogenic survival assays each work via three different mechanisms to exploit repair 
deficiencies (see section 1.11 Targeted therapy in clinical cancer care).  BRCA1 and BRCA2 are 
the most highly penetrance HBOC associated genes and BRCA1 and BRCA2 deficient cells are 
particularly sensitive to all three of these chemotherapeutic reagents.  Cells deficient in tumor 
suppressor genes that are BRCA-like but moderate in penetrance, such as ATM, RAD51D and 
CHEK2, display significant but less or no increased cytotoxicity to each of these three reagents.  
Therefore, in assessing the extent to which a gene is BRCA-like, it seems rationale to take into 
consideration the sensitivity to all three of these reagents; Cisplatin, Etoposide and Olaparib 
versus a single reagent alone.  
To test this assumption, four plots were generated each with reduction in cell viability 
observed without drug exposure on the Y axis and cytotoxicity observed after DNA damage on 
the X axis.  Figure 13A features a plot that includes the pooled cytotoxicity data across all three 
tested reagents; Cisplatin, Etoposide and Olaparib.  The subsequent plots were generated by only 
accounting for cytotoxicity to each drug alone; Cisplatin; Figure 13B, Etoposide; Figure 13C, 
and Olaparib; Figure 13D.  Since we know the penetrance of the panel genes plotted (listed in 
Figure 13), we can see that the first plot (Figure 13A) which features the pooled sensitivity data 
across all three reagents is most accurate.  With this plot, highly penetrant genes BRCA1 and 
BRCA2 fall in top most section of both DNA damage sensitivity and reduction of cellular 
viability (upper right), while the scramble control falls in the lowest section of both conditions 
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(lower left).  Panel genes ATM, RAD51D and CHK2, known to be of moderate penetrance, fall in 
the middle of the graphical representation.   
The statistical data generated from pooling all conditions (cell viability after knockdown 
alone, and cytotoxicity to Cisplatin, Etoposide and Olaparib after siRNA knock down) is 
represented in Table 11.  The overall survival of cells with siRNA scramble control was 49.6%, 
which is expected due to the IC50 optimization of drugs and normal plating efficiency of HeLa 
cells.  The survival of BRCA1 deficient cells across all conditions was 22% (p=<0.00) and 
BRCA2 was 15% (p=<0.00).  All moderately penetrant genes fell in a range of 30-39% survival 
across all conditions and were all statistically significant. The statistical data and geographical 
clustering based on these data observed across panel genes tested are concordant with the current 
penetrance estimates in the literature, and with what clinicians refer to for genetic counseling and 
risk management.  Therefore, this methodology could potentially be useful in estimating 
candidate gene penetrance. 
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 Breast Ovarian Penetrance 
ATM 17%-52% unknown Moderate 
CHK2 23-48% unknown Moderate 
RAD51D unknown 14.8% Moderate 
BRCA1 46%-87% 39%-63% High 
BRCA2 43%-84% 15%-27% High 
 
       
      Lifetime risks for breast and ovarian cancer determine penetrance 
      Stats provided by Myriad Genetics (https://myriad.com/) 
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Figure 13. Plotting panel genes based on cell viability and pooled DNA damage sensitivity 
after siRNA knock down correctly differentiates between moderate and high penetrance.  
A. Plot with pooled DNA damage sensitivity data across all three reagents correctly indicates 
ATM, RAD51D, CHK2 as moderately penetrance and BRCA1 and BRCA2 as high penetrant. B. 
Etoposide incorrectly estimates CHK2 as highly penetrant and BRCA1 as moderately penetrant.  
C. Cisplatin incorrectly estimates CHK2 as a highly penetrant gene D. Analysis of Olaparib 
alone groups ATM with scramble control.  
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5.4.2 CHK1 and RAD1 predicted as moderate to high and TP53I3 as moderate penetrant 
genes 
As previously discussed, plotting panel genes based on cell viability and pooled 
cytotoxicity to DNA damage after siRNA knock down may differentiate between moderate and 
high penetrance.  In total, six control data points; scramble (SCR), ATM, CHK2, RAD51D, 
BRCA1 and BRCA2 represent an accurate comparison for estimating the penetrance of candidate 
genes.  I therefore plotted these data points once more alongside non-panel candidate genes.  
Again, with reduction in cell viability observed without drug exposure on the Y axis and 
cytotoxicity observed after DNA damage (Cisplatin, Etoposide, Olaparib) on the X axis (Figure 
14). Table 11 lists the statistical data from overall survival across all conditions by siRNA 
knockdown.   
In this analysis, MCM4, HMMR and REC8 were observed to cluster with the scramble 
(SCR) control suggesting they are unlikely to be BRCA-like tumor suppressor genes.  There is no 
statistical difference between these candidate genes and the scramble control in overall mean 
survival.  While REC8 deficient cells showed low but significant sensitivity to Etoposide 
treatment, the difference between scramble control and pooled DNA treatment sensitivity plus 
plating efficiency (cell viability after knock-down) was insignificant (p=0.06).  In the plot for 
estimating penetrance, candidate gene TP53I3 clustered with moderately penetrant genes and had 
a survival of 36% (p=<0.001) across all conditions versus the survival of cells with siRNA 
scramble control at 49.6%.  CHK1 fell in a graphical position indicative of a gene with moderate 
to high penetrance as the loss of cellular viability without DNA damage was observed as similar 
to BRCA1 and BRCA2, however the sensitivity observed in response to DNA damaging reagents 
was similar to moderately penetrant genes. The mean pooled survival for cells deficient in CHK1 
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for all conditions was 32.7% (p=0.001).  Of all candidate genes assayed, RAD1 was shown to be 
the most impactful regarding cell survival and cytotoxicity to DNA damage.  Cells deficient for 
this gene had a survival rate of 26.8% (p=<0.001) across all conditions and this gene fell close to 
BRCA1 and BRCA2 on the graphical representation of estimated penetrance, indicating that it 
may be a highly penetrant gene (Table 11). 
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Figure 14. Penetrance estimates based on clustering with known risk genes  
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  Scramble 49.6 8.3 --- --- --- 
P
a
n
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ATM 37.5 19.89 12.0 -2.60 0.015 
BRCA1 22.2 15.54 27.4 -7.71 0.000 
BRCA2 14.8 10.27 34.7 -13.34 0.000 
CHK2 30.1 12.95 19.5 -6.30 0.000 
RAD51D 38.6 12.92 11.0 -3.72 0.001 
N
o
n
-P
a
n
el
 
FANCM 2.1 1.83 47.5 -26.9 0.000 
CHK1 32.7 19.70 16.8 -3.89 0.001 
HMMR 46.5 13.79 3.0 -0.96 0.342 
MCM4 48.4 12.17 1.2 -0.41 0.684 
RAD1 26.8 13.12 22.8 -7.31 0.000 
REC8 44.1 11.51 5.5 -1.89 0.066 
TP53I3 36.0 11.61 13.6 -4.90 0.000 
 
Table 11. Statistical data for pooled survival rates across all clonogenic survival conditions; 
no drug, Cisplatin, Etoposide and Olaparib. M = Mean % survival, SD = Standard deviation, 
MD = mean difference as compared to scramble control.  t = statistical test for mean difference, 
p-values in bold are significant. 
 
Pooled survival rates (%) 
all conditions  
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CHAPTER 6: DISCUSSION PART II 
6.1 Functional analyses compliment bioinformatics and strengthen cases for various 
novel risk genes 
During WES analysis, various candidate genes were found with loss of function 
mutations in women with OVCA and high risk of genetic inheritance.  While compelling 
variants are often identified through WES/WGS, they remain putative risk loci until proven 
otherwise.  Because high risk variants are rare, and hereditary OVCA has a great deal of 
heterogeneity, implicating a novel gene or variant based on enrichment in cases versus controls 
is unlikely.  Additionally, implicating a variant based on segregation is not ideal due to 
incomplete penetrance and lack of informative family members.   Bioinformatic tools alone are 
not sensitive enough to direct clinical decisions but are useful for variant filtering purposes.   
This study is unique in its ability to identify novel risk loci for two main reasons; first, 
WES was carried out on a very select group of patients with high risk of genetic inheritance, yet 
with no known pathogenic variant.  Second, candidate loci identified by well-established 
bioinformatics techniques were followed up by functional assessment using sensitive wet lab 
techniques.  This approach identified four novel genes; FANCM, CHK1, RAD1 and TP53I3 as 
having the BRCA-like phenotype typically observed in tumor suppressor genes commonly 
mutated the germline of women with inherited risk of breast and/or ovarian cancer.   
In this study, siRNA knock-down of FANCM led to a reduction in homologous 
recombination repair and large loss of clonogenic survival similar to that observed in BRCA1 or 
BRCA2 deficient cells.  Because of the large loss in cell survival after knock-down, it could not 
be assayed for cytotoxicity to Cisplatin, Olaparib, or Etoposide after knock-down and therefore 
an estimate of this gene’s penetrance could not be established.  However, the functional data 
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from this study, along with the family pedigree of the FANCM carrier (Figure 7), and association 
with familial breast cancer in recent literature (Peterlongo et al. 2015) is supportive of high risk.  
Additionally, mouse model data describes FANCM homozygous knock outs as having decreased 
life span and increased cancer incidence (Bakker et al., 2009). 
Candidate gene CHK1, like panel gene CHK2, encodes for a serine/threonine protein 
kinase required for checkpoint-mediated cell cycle arrest and activation of DNA repair by 
homologous recombination repair. This gene is highly conserved, and the c.1564-1565insA 
frameshift variant identified by WES in this study sample is novel.  In this study, siRNA knock 
down of CHK1 lead to a loss of HRR efficiency, reduction in cellular viability, and increased 
sensitivity to Cisplatin and Etoposide similar to that of observed in BRCA1/BRCA2 deficient 
cells.  Loss of function of this gene is predicted to be moderate to highly penetrant in cancer risk 
as it clusters with known high and moderate penetrant tumor suppressor genes on a 2-
dimensional model of cell viability and cytotoxicity to DNA damage.  These results are 
consistent with mouse model phenotypes describing homozygote nulls are embryonic lethal, and 
heterozygote knock-outs display enhanced tumorigenesis (Q. Liu et al., 2000).  Recently, CHK1 
has been identified as an important biomarker for chemotherapy response in breast cancer (Al-
Kaabi et al. 2015) and the deletion of CHK1 is a common genetic event that occurs in the 
beginning stages of breast cancer development (Mu et al., 2011).  Loss of heterozygosity is likely 
to have occurred in the carrier of the CHK1 frameshift.  Unfortunately, the patient declined 
tumor tissue usage, and this could not be confirmed.  The fact that CHK1 has not already been 
implicated in in hereditary risk of ovarian or breast cancer is likely because pathogenic variants 
in this gene are extremely rare.  
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Another novel loss of function variant was uncovered in RAD1.  Knock out mouse 
models of this gene describe embryonic lethality in homozygotes and larger, more numerous, 
earlier onset skin tumors with DMBA-TPA treatment in heterozygotes (L. Han et al., 2010).  In 
this study, siRNA knock down of RAD1 led to decreased cellular viability and increased 
sensitivity to Cisplatin, and Etoposide similar to that observed with knock down of BRCA1 and 
BRCA2.  However, RAD1 depletion did not lead to a reduction in HRR efficiency.  This indicates 
that RAD1 may be involved in DNA repair via a mechanism other than HRR.  Most of what is 
known regarding RAD1 functional activity is derived from yeast studies.  RAD1 is a part of the 
9-1-1 cell cycle checkpoint complex to arrest cellular proliferation in the presence of incomplete 
DNA replication or damaged DNA.  This complex has also been shown to participate in DNA 
repair by forming a clamp to facilitate resection of DNA double strand breaks points (Ngo and 
Lydall 2015).  One study has shown RAD1 as indispensable to microhomology-mediated end 
joining (MMEJ) for the repair of ionizing radiation and chemicals that induce DSBs (Ma et al. 
2003).  Another study in yeast identified RAD1 mutants as hyper sensitive to platinum (Perego et 
al. 1998).  While the human orthologue of yeast Rad1 is not well described in the literature, the 
observation of a germline RAD1 LOF variant in an OVCA patient considered at high risk of 
genetic inheritance, plus the results of this study’s functional analyses in a human cervical cell 
line makes a compelling case for this gene as a risk factor.  The scale of penetrance developed in 
this study estimates the LOF of RAD1 to be high risk.  The carrier of the RAD1 frameshift 
variant developed OVCA at the age of 65, and had a family history of colon, breast (n=2), 
prostate, lung, and leukemia all of which on one parental side of the family, which is indicative 
of a highly penetrant germline risk variant.  Unfortunately, segregation analysis was not possible 
since DNA samples from her deceased family members are not available.   
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TP53I3 is an oxidoreductase-like protein and an inducer of ROS, that is transcriptionally 
activated by the tumor suppressor TP53 and likely to be involved in TP53-mediated apoptosis 
(Zhang et al. 2015).  A nonsense SNP in this gene was observed twice in this study sample 
amongst unrelated individuals, despite its rarity (rs145078765, p.S252*, MAF= 0.0009). The 
functional analysis of this gene during this study indicated that loss of TP53I3 leads to a 
moderate reduction in HRR efficiency as well as increased cell sensitivity to Cisplatin.  Loss of 
function of this gene is predicted to be moderately penetrant in cancer risk as it clusters with 
known moderately penetrant tumor suppressor genes on a 2-dimensional graphical representation 
of cell viability and DNA sensitivity. 
Another candidate gene assessed in this study was REC8, which encodes for a cohesin 
complex protein required for the structural maintenance of chromosomes during meiosis. 
Cohesions are necessary to join sister chromatids together until DNA replication is complete. 
Rec8 functional studies in yeast described it as a meiosis-specific (Yoon et al. 2016).  However, 
in this study, siRNA reduction of REC8 led to a decrease in DNA repair by homologous 
recombination and increased sensitivity to Etoposide. Because the pooled data across all 
clonogenic survival conditions did not reach not significance (p=.06), this may indicate that 
REC8 LOF would be of minimal risk, and possibly a modifier of penetrance.  However, as 
mentioned previously, the methods employed in this study are specific to capture a BRCA-like 
tumor suppressor phenotype.  It is possible that the tumor suppressor functions of REC8 are 
mostly independent of DNA repair pathway.  Recently, investigators identified REC8 as a tumor 
suppressor gene epigenetically downregulated in gastric cancer (Yu et al. 2017).  Another study 
showed that epigenetic silencing of REC8 was robustly associated with PI3K pathway alterations 
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in thyroid tumors, possibly encouraging the oncogenic properties of the PI3K/AKT/mTOR 
pathway, which is important to cell cycle regulation (D. Liu et al., 2015).  
6.2 A Novel scale for estimating penetrance through a 2-dimensional model of cell 
viability and DNA sensitivity 
Most cancer-associated risk loci have incomplete penetrance. The penetrance of a 
pathogenic variant is determined by its associated lifetime risk with disease, and accurate 
estimates of genetic penetrance are necessary to inform clinical decisions.  Genes are often 
described as having low, moderate, or high penetrance based on the lifetime risk associated with 
a loss of function variant.  Unfortunately, lifetime risk estimates are difficult to obtain with rare 
variants and even well-established cancer risk loci can have unknown penetrance.  Currently, 
there exists no laboratory-based functional method for the specific purpose of estimating 
penetrance of genetic loci in HBOC.   
Candidate tumor suppressors are often assayed in conjunction with a BRCA1 or BRCA2 
positive control since these genes are the two most highly penetrant in HBOC risk.  The term 
“BRCAness” or “BRCA-like” has come to describe other tumor suppressor genes that lead to 
similar phenotypes with loss of function, such as sensitivity to DNA damage and loss of cell 
viability.  Various HBOC risk loci that possess BRCA-like tumor suppressor properties have been 
implicated in the last decade.  Many risk loci are described as moderately penetrant due to 
lifetime risks estimated to be much higher than the general population, yet much lower than 
BRCA1 or BRCA2.  In this study, all lab experimental designs incorporated the use of five 
positive controls for the comparison of novel candidate risk genes to two highly and three 
moderately penetrant established risk genes in the context of BRCA-like tumor suppressor 
properties.   
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The assays employed in this study were sensitive enough to implicate all five established 
HBOC cancer risk genes tested.  Importantly, a pooled analysis of cell viability and cytotoxicity 
to DNA damage was able to clearly distinguish between moderate and high-risk genes in a 2-
dimentional geographical representation. Notably, this technique estimated candidate genes 
CHK1 and RAD1 as moderate to high and TP53I3 as moderately penetrant genes.   
While preliminary, this scale has the potential to functionally validate additional 
candidate genes identified by other WES studies and possibly estimate the penetrance of certain 
established HBOC risk genes with unknown lifetime risk profiles (RAD50, BRIP1, BARD1, etc.)  
This approach could eventually serve as a tool to better inform clinical management of certain 
patients.  Genetic testing clinics that engage in research may choose to employ this methodology 
to help in closing the gap in missing heritability of this disease.   
6.3 Limitations and Future Directions 
It is important to note the various limitations of this study.  Firstly, because WES targets 
exonic DNA, it was only possible to analyze the protein coding and closely surrounding regions 
on the genome in these high-risk women.  While bioinformatic analysis was performed on the 
1000 bps captured upstream of the exons of panel genes, no suspicious variants were uncovered 
in either promoter or splice donor/acceptor loci.  Additionally, large copy number variants 
(CNVs) are not readily detectable through WES data and could be a source of missing 
heritability.  Using ExomeDepth, an R package which relies on read depth to indirectly infer 
deletions or duplications, I was able to analyze all exomes for possible CNVs in panel genes, but 
no true calls were detected (data not shown).   
Additionally, the candidate gene analysis performed was primarily focused on DNA 
repair and cell cycle control as these are the two most commonly mutated pathways in HBOC.  It 
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is likely that risk loci occur outside of these pathways and further analyses of these exomes 
should be performed with this in mind.  However, one important consideration in pathway 
analysis of WES data is that it is far easier to determine that a variant leading to a loss of 
function versus a gain of function by sequence change.   
Furthermore, it must be emphasized that the penetrance estimates derived from functional 
studies are specific to a loss of function risk loci in BRCA-like tumor suppressor genes involved 
in cell viability and/or DNA repair.  Accordingly, the functional analysis employed in this study 
suggests that candidate genes REC8, HMMR, and MCM4 lack the “BRCA-ness” tumor 
suppressor phenotype typically observed in breast and ovarian cancer risk genes.  However, we 
cannot say for certain that they are not risk factors by other means.  Still, the overall approach 
may be applicable to develop similar penetrance estimate scales specific to other cancer related 
pathways.  Additionally, the use of siRNA for gene depletion is not optimal since the various 
siRNA have different knock down efficiencies.  This makes it difficult to accurately compare 
phenotypic outcomes by gene knockdown. Finally, because this methodology is new, it should 
be further validated, refined, and replicated in additional cell lines, and preferably by employing 
gene knock out techniques in place of mRNA depletion.  
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APPENDIX 
 
Table 12. Rare missense variants in non-HBOC panel genes involved in DNA repair or cell 
cycle control and are associated with cancer phenotypes in HGMD. MAF=Minor Allele 
Frequency in (ExAC Non-Finnish Europeans.).  DEL= Deleterious TOL= Tolerated, N/A= 
Information not available, *Variants in these genes were not confirmed by Sanger DNA 
sequencing. 
 
Gene Amino 
Acids 
dbSNP ID MAF OBS HGMD (cancer phenotype 
associated with gene) 
SIFT Polyphen 
APEX1* P248L rs201100630 0.00005 1 Head and Neck DEL Benign 
AXIN1 V340M rs143974067 0.00004 1 Colorectal adenoma DEL Probably Damaging 
BUB1B E409D rs28989188 0.0004 1 Gastrointestinal TOL Probably Damaging 
CASP10* I406L rs80358239 0.004 1 Autoimmune lymphoproliferative 
syndrome II 
TOL Possibly Damaging 
ERCC4* E875G rs1800124 0.019 1 Lung, Cockayne, Xeroderma 
pigmentosa, Breast/Ovarian, 
Fanconi anaemia, 
DEL Possibly Damaging 
ERCC6 M713V rs201486862 0.00006 1 Cockayne syndrome, basal cell 
carcinoma,  
DEL Benign 
EXO1* D270V rs201509012 0.0005 1 Colorectal  DEL Possibly Damaging 
EXO1* G759E rs4150001 0.009 1 Colorectal TOL Benign 
FANCA* T475M N/A N/A 1 Fanconi Anemia DEL Possibly Damaging 
FANCA* A602G N/A N/A 1 Fanconi Anemia DEL Possibly Damaging 
FANCF* P320L rs45451294 0.017 2 Fanconi Anemia  TOL Probably Damaging 
MLH3* V741F rs28756990 0.006 1 Colorectal, Breast/Ovarian,  TOL Possibly Damaging 
PALLD* R303S rs138897963 0.001 1 Pancreatic TOL Probably Damaging 
PMS1* T75I rs61756360 0.0008 1 Breast/ovarian DEL Probably Damaging 
RAD50* T191I rs2230017 0.0007 1 Breast/Ovarian DEL Benign 
RBL1* R199H N/A N/A 1 Multiple adenoma DEL Probably Damaging 
RBL1* E624Q N/A N/A 1 Multiple adenoma TOL Possibly Damaging 
RECQL C321Y rs150889040 0.00001 1 Breast N/A N/A 
WRN* T573A rs150148567 0.001 1 Colorectal, Breast, Pancreatic, 
Werner syndrome 
DEL Probably Damaging 
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Figure 15. Western blots for siRNA knock down. Lysates from functional assays indicating 
protein expression with scramble (+) and reduction of same protein with targeted siRNA knock 
down (-) compared to Actin or Vinculin loading control.     
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ABSTRACT 
 
MISSING HERITABILITY AND NOVEL GERMLINE RISK LOCI IN HEREDITARY 
OVARIAN CANCER: INSIGHTS FROM WHOLE EXOME SEQUENCING AND 
FUNCTIONAL ANALYSES 
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Degree: Doctor of Philosophy 
While 25% of ovarian cancer (OVCA) cases are due to inherited factors, most of the 
genetic risk remains unexplained. This study addressed this gap by identifying previously 
undescribed OVCA risk loci through the whole exome sequencing (WES) of 48 BRCA1/BRCA2 
wild type women diagnosed with OVCA, selected for high risk of genetic inheritance. Five 
clearly pathogenic variants were identified in this sample, four of which are in two genes 
featured on current multi-gene panels; (RAD51D, ATM). In addition, a high impact variant in 
FANCM (R1931*) was identified.  FANCM has been recently implicated in familial breast 
cancer risk but is not yet featured on testing panels.  Numerous rare and predicted to be 
damaging variants of unknown significance were detected in genes on current commercial 
testing panels.  Also, the BRCA2 variant p.K3326*, considered benign but resulting in a 93 
amino acid truncation, was overrepresented in our sample (OR= 4.95, p=0.01) and coexisted in 
the germline of these women with other deleterious variants, suggesting a possible role as a 
modifier of genetic penetrance.  
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A candidate gene analysis detected loss of function (LOF) variants in genes involved in 
OVCA relevant pathways; DNA repair and cell cycle control, including FANCM, CHK1, 
TP53I3, REC8, HMMR, RAD1, and MCM4. Wet lab functional assessment implicated FANCM, 
CHK1, RAD1 and TP53I3 as having the BRCA-like phenotype typically observed in tumor 
suppressor genes commonly mutated the germline of women with inherited risk of breast and/or 
ovarian cancer.  Importantly, plotting various panel genes based on cell viability and sensitivity 
to DNA damage after siRNA knock down correctly differentiated between moderate and high 
penetrant genes. This technique identified candidate genes CHK1 and RAD1 as high and TP53I3 
as moderate in penetrance.  
The results of this project indicate that WES on study samples filtered for family history 
and negative for known causal variants is the most appropriate study design for identifying rare 
and novel high-risk variants. This study implicates novel risk loci as well as highlights the 
necessity of wet lab functional assessment.  Importantly, this study also suggests that wet lab 
assays may be employed to differentiate moderate from high risk genetic loci.  
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